Accuray (ARAY) 10-K 25 Aug 20 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2020	Aug. 16, 2020	Dec. 31, 2019
Cover [Abstract]
Entity Registrant Name	ACCURAY INCORPORATED
Entity Central Index Key	0001138723
Document Type	10-K
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Trading Symbol	ARAY
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 176,031,250
Entity Common Stock, Shares Outstanding		91,198,408
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Shell Company	false
Entity Small Business	false
Entity Emerging Growth Company	false
Entity File Number	001-33301
Entity Tax Identification Number	20-8370041
Entity Address, Address Line One	1310 Chesapeake Terrace
Entity Address, City or Town	Sunnyvale
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94089
City Area Code	408
Local Phone Number	716‑4600
Entity Incorporation, State or Country Code	DE
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, $0.001 par value per share
Security Exchange Name	NASDAQ
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the Proxy Statement for the Registrant’s 2020 Annual Meeting of stockholders (the “2020 Proxy Statement”) are incorporated by reference in Part III of this Form 10‑K.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands		Jun. 30, 2020	Jun. 30, 2019
Current assets:
Cash and cash equivalents		$ 107,577	$ 76,798
Restricted cash		997	10,218
Accounts receivable, net of allowance for doubtful accounts of $1,268 and $605 as of June 30, 2020 and June 30, 2019, respectively	[1]	90,599	111,885
Inventories, net		134,374	120,823
Prepaid expenses and other current assets		21,227	24,205
Deferred cost of revenue		2,712	146
Total current assets		357,486	344,075
Property and equipment, net		15,349	17,122
Investment in joint venture		13,929
Operating lease right-of-use assets, net		28,647	30,578
Goodwill		57,717	57,770
Intangible assets, net		663	679
Restricted cash		1,337	1,162
Other assets		15,799	17,373
Total assets		490,927	438,181
Current liabilities:
Accounts payable		23,126	29,562
Accrued compensation		17,963	31,150
Operating lease liabilities, current		8,224
Other accrued liabilities		27,180	32,742
Customer advances		22,571	20,395
Deferred revenue		83,207	78,332
Total current liabilities		182,271	192,181
Long-term liabilities:
Operating lease liabilities, non-current		24,173
Long-term other liabilities		7,416	9,646
Deferred revenue		24,125	26,639
Long-term debt		189,307	159,844
Total liabilities		427,292	388,310
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized: 5,000,000 shares; no shares issued and outstanding
Common stock, $0.001 par value; authorized: 200,000,000 shares as of June 30, 2020 and June 30, 2019, respectively; issued and outstanding: 91,178,108 and 88,521,511 shares at June 30, 2020 and June 30, 2019, respectively		91	89
Additional paid-in-capital		545,741	535,332
Accumulated other comprehensive loss		(484)	(10)
Accumulated deficit		(481,713)	(485,540)
Total stockholders' equity		63,635	49,871
Total liabilities and stockholders’ equity		$ 490,927	$ 438,181
[1]	Include accounts receivable from the China joint venture of $3,039 and $0 at June 30, 2020 and June 30, 2019, respectively. See Note 13

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 1,268	$ 605
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized shares	200,000,000	200,000,000
Common stock, issued shares	91,178,108	88,521,511
Common stock, outstanding shares	91,178,108	88,521,511
Accounts receivable from joint venture	$ 3,039	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands		12 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Net revenue:
Total net revenue	[1]	$ 382,928	$ 418,785	$ 404,897
Cost of revenue:
Total cost of revenue	[2]	233,207	256,134	243,202
Gross profit		149,721	162,651	161,695
Operating expenses:
Research and development		49,784	56,493	57,251
Selling and marketing		47,254	55,998	60,105
General and administrative		40,144	49,577	48,136
Total operating expenses		137,182	162,068	165,492
Income (loss) from operations		12,539	583	(3,797)
Loss on equity method investment		(149)
Other expense, net		(6,700)	(14,927)	(19,224)
Income (loss) before provision for income taxes		5,690	(14,344)	(23,021)
Provision for income taxes		1,863	2,086	878
Net income (loss)		$ 3,827	$ (16,430)	$ (23,899)
Net income (loss) per share - basic		$ 0.04	$ (0.19)	$ (0.28)
Net income (loss) per share - diluted		$ 0.04	$ (0.19)	$ (0.28)
Weighted average common shares used in computing net income (loss) per share:
Basic		89,874	87,465	84,893
Diluted		90,623	87,465	84,893
Net income (loss)		$ 3,827	$ (16,430)	$ (23,899)
Foreign currency translation adjustment		(238)	(247)	83
Reclassification adjustments on available for sale investments, net of tax				89
Change in defined benefit pension obligation		(236)	(856)	973
Comprehensive income (loss)		3,353	(17,533)	(22,754)
Products
Net revenue:
Total net revenue		167,302	196,665	183,898
Cost of revenue:
Total cost of revenue		95,882	116,711	103,038
Services
Net revenue:
Total net revenue		215,626	222,120	220,999
Cost of revenue:
Total cost of revenue		$ 137,325	$ 139,423	$ 140,164
[1]	Includes sales to the China joint venture, an equity method investment of $19,054 for the year ended June 30, 2020 and $0 for both years ended June 30, 2019 and June 30, 2018, respectively. See Note 13.
[2]	Includes cost of revenue from sales to the China joint venture, an equity method investment of $13,174 for the year ended June 30, 2020 and $0 for both years ended June 30, 2019 and June 30, 2018, respectively. See Note 13.

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Income (Loss) (Parenthetical) - USD ($) $ in Thousands		12 Months Ended
		Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Total net revenue	[1]	$ 382,928	$ 418,785	$ 404,897
Total cost of revenue	[2]	233,207	256,134	243,202
Revenue from Joint Venture
Total net revenue		19,054	0	0
Total cost of revenue		$ 13,174	$ 0	$ 0
[1]	Includes sales to the China joint venture, an equity method investment of $19,054 for the year ended June 30, 2020 and $0 for both years ended June 30, 2019 and June 30, 2018, respectively. See Note 13.
[2]	Includes cost of revenue from sales to the China joint venture, an equity method investment of $13,174 for the year ended June 30, 2020 and $0 for both years ended June 30, 2019 and June 30, 2018, respectively. See Note 13.

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Jun. 30, 2017	$ 46,533	$ 84	$ 496,887	$ (52)	$ (450,386)
Balance (in shares) at Jun. 30, 2017		83,739,804
Exercise of options, net	437		437
Exercise of options, net (in shares)		108,800
Issuance of restricted stock		$ 1	(1)
Issuance of restricted stock (in shares)		1,166,776
Issuance of common stock under employee stock purchase plan	3,334	$ 1	3,333
Issuance of common stock under employee stock purchase plan (in shares)		921,583
Share-based compensation	12,289		12,289
Tax withholding upon vesting of restricted stock units	(293)		(293)
Tax withholding upon vesting of restricted stock units (in shares)		(61,536)
Retirement of Convertible Senior Notes	288		288
Retirement of Convertible Senior Notes (in shares)		253,829
Allocated transaction cost in debt issuance	8,798		8,798
Net income (loss)	(23,899)				(23,899)
Cumulative translation adjustment	83			83
Reclassification adjustments on available for sale investments, net of tax	89			89
Change in defined benefit pension obligation	973			973
Balance at Jun. 30, 2018	48,632	$ 86	521,738	1,093	(474,285)
Balance (in shares) at Jun. 30, 2018		86,129,256
Exercise of options, net	489		489
Exercise of options, net (in shares)		114,932
Issuance of restricted stock		$ 2	(2)
Issuance of restricted stock (in shares)		1,491,379
Issuance of common stock under employee stock purchase plan	3,022	$ 1	3,021
Issuance of common stock under employee stock purchase plan (in shares)		911,741
Share-based compensation	10,086		10,086
Tax withholding upon vesting of restricted stock units (in shares)		(125,797)
Adoption of new revenue recognition standard	5,175				5,175
Net income (loss)	(16,430)				(16,430)
Cumulative translation adjustment	(247)			(247)
Change in defined benefit pension obligation	(856)			(856)
Balance at Jun. 30, 2019	$ 49,871	$ 89	535,332	(10)	(485,540)
Balance (in shares) at Jun. 30, 2019	88,521,511	88,521,511
Issuance of restricted stock	$ (206)	$ 1	(207)
Issuance of restricted stock (in shares)		1,579,037
Issuance of common stock under employee stock purchase plan	2,451	$ 1	2,450
Issuance of common stock under employee stock purchase plan (in shares)		1,136,096
Share-based compensation	8,166		8,166
Tax withholding upon vesting of restricted stock units (in shares)		(58,536)
Net income (loss)	3,827				3,827
Cumulative translation adjustment	(238)			(238)
Change in defined benefit pension obligation	(236)			(236)
Balance at Jun. 30, 2020	$ 63,635	$ 91	$ 545,741	$ (484)	$ (481,713)
Balance (in shares) at Jun. 30, 2020	91,178,108	91,178,108

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities
Net income (loss)	$ 3,827	$ (16,430)	$ (23,899)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	7,541	10,491	9,732
Share-based compensation	8,152	10,601	12,289
Amortization of debt issuance costs	1,348	1,528	1,629
Amortization and accretion of discount and premium on investments			(15)
Loss on sales of investments			171
Accretion of interest on debt	4,168	3,371	3,376
Provision for (recovery of) bad debt, net	1,797	3,681	(73)
Provision for write-down of inventories	4,184	2,340	1,603
(Gain) loss on disposal of property and equipment	9	2,588	(8)
Loss on equity method investment	149
Elimination of equity method investment intra-entity profit on sales	1,847
Loss on extinguishment of debt			3,452
Gain on termination of lease obligation		(1,007)
Gain on contribution to joint venture	(12,964)
Provision (benefit) for deferred income taxes	353	(86)	30
Changes in assets and liabilities:
Accounts receivable, short and long-term	19,030	(46,165)	7,223
Inventories	(23,178)	(14,165)	(8,685)
Prepaid expenses and other assets	4,403	(13,049)	4,209
Deferred cost of revenue, short and long-term	(2,441)	531	2,422
Accounts payable	(6,770)	9,456	2,002
Operating lease liabilities, net	(235)
Accrued liabilities	(16,242)	10,857	1,577
Customer advances	2,159	(2,549)	6,189
Deferred revenues, short and long-term	1,747	8,366	(4,893)
Net cash provided by (used in) operating activities	(1,469)	(29,641)	18,331
Cash flows from investing activities
Purchases of property and equipment, net	(3,558)	(4,311)	(6,276)
Purchase of intangible assets	(170)		(333)
Purchases of investments			(5,940)
Sales and maturities of investments			30,315
Net cash provided by (used in) investing activities	(3,728)	(4,311)	17,766
Cash flows from financing activities
Proceeds from employee stock plans	2,450	3,927	4,389
Taxes paid related to net share settlement of equity awards	(207)		(293)
Payments made to note and loan holders			(69,797)
Proceeds from debt, net of costs	24,716	19,968	66,111
Borrowings (repayments) under Revolving Credit Facility, net	(263)	4,578	(27,863)
Net cash provided by (used in) financing activities	26,696	28,473	(27,453)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	234	124	(346)
Net increase (decrease) in cash, cash equivalents and restricted cash	21,733	(5,355)	8,298
Cash, cash equivalents and restricted cash at beginning of period	88,178	93,533	85,235
Cash, cash equivalents and restricted cash at end of period	109,911	88,178	93,533
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	2,806	2,191	1,460
Cash paid for interest	12,332	9,761	9,187
Supplemental non-cash disclosure:
Non-cash effect of pension settlement accounting	178
Exchange of Convertible Notes			6,641
Modification of Revolving Credit Facility			1,997
Unpaid purchase of property and equipment at end of year	226	235	399
Transfers from inventory to property and equipment	2,594	$ 1,170	$ 174
An equity method investment, in exchange for non-cash contributions of assets to China Joint Venture (including gain of $12,964)	$ 15,925

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Jun. 30, 2020USD ($)
Statement Of Cash Flows [Abstract]
Gain on contribution to equity method investment	$ 12,964

The Company and its Significant

The Company and its Significant Accounting Policies	12 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
The Company and its Significant Accounting Policies	Note 1. The Company and its Significant Accounting Policies The Company Accuray Incorporated (together with its subsidiaries, the “Company” or “Accuray”) designs, develops and sells advanced radiosurgery and radiation therapy systems for the treatment of tumors throughout the body. The Company is incorporated in Delaware and has its principal place of business in Sunnyvale, California. The Company has primary offices in the United States, Switzerland, China, Hong Kong and Japan and conducts its business worldwide. Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with United States accounting generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the coronavirus disease (“COVID-19”) pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the effects of and response to the pandemic are rapidly evolving and new information is regularly coming to light. The Company's customers are diverting resources to treat COVID-19 patients and deferring non-urgent and elective procedures, both of which are likely to impact customers' ability to meet their other financial obligations, including to the Company. Some customers, which include hospitals, major academic medical centers, and other related entities, have incurred significant losses during the COVID-19 pandemic due to reduced patient volume. Furthermore, the Company is also anticipating a global economic slowdown due to disruptions caused by the COVID-19 pandemic, which may result in an incremental adverse impact on revenue, net income and cash flow and may require significant additional expenditures to mitigate such impacts. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The Company’s financial results have also been affected by the COVID-19 pandemic in various ways. The COVID-19 pandemic is adversely impacting the pace at which the backlog converts to revenue in the near-term. This is primarily the result of delays in the timing of deliveries and installations in fiscal 2020 due to timing delays caused by the COVID-19 pandemic, which resulted in a decline to the revenue for the same period. The Company expects that such delays in deliveries and installations will continue into fiscal 2021, which could have a negative impact on the revenue during those periods. As of the date of this Form 10-K, the Company experienced disruptions in the sales and revenue cycle as well as increases in customer defaults, delays in payment and planned installations and service agreements as a result of the effect of the COVID-19 pandemic on the Company’s customers as well as restrictions imposed on travel. The Company also received requests from a few customers to extend payment terms or temporarily suspend service and corresponding payment obligations and while the Company have only received a small number of requests thus far, there can be no guarantee that more customers will not ask for the same if the effects of the COVID-19 pandemic deepen or worsen. As a result, the Company is carefully monitoring the pandemic and the resulting length and depth of the economic impact on our financial condition and results of operations, however, given the uncertainty regarding the spread and potential resurgence of COVID-19 and how long the pandemic will last, the related financial impact cannot be reasonably estimated at this time, although the impacts are expected to continue and may also significantly affect the Company’s business. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. In addition, the Company is unable to predict with certainty the impact of the COVID-19 pandemic on its ability to maintain compliance with the debt covenants contained in the credit and security agreements related to its Revolving Credit Facility and Term Loan (as such terms are defined in Note 10 below), including financial covenants regarding the fixed charge coverage ratio, minimum net revenue, minimum consolidated cash balance and minimum consolidated domestic cash balance tests. The Company was in compliance with such covenants for the quarter ended June 30, 2020, as amended. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be Subsequent Events Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. Key estimates and assumptions made by the Company relate to revenue recognition, assessment of recoverability of goodwill and intangible assets, valuation of our equity method investment in the JV, valuation of inventories, share‑based compensation expense, convertible notes, income taxes, allowance for doubtful accounts and loss contingencies. Actual results could differ materially from those estimates. Foreign Currency The Company’s international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at the average exchange rate. Resulting translation adjustments are excluded from the determination of net loss and are recorded in accumulated other comprehensive loss as a separate component of stockholders’ equity. Net foreign currency exchange transaction gains or losses are included as a component of other expense, net, in the Company’s consolidated statements of operations and comprehensive income (loss). Fair Value Measurements The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short‑term nature of these instruments. Also refer to Note 8, Fair Value Measurements, Cash and Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States and internationally. Concentration of Credit Risk and Other Risks and Uncertainties The Company’s cash and cash equivalents are mainly deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. The Company had no customer that represented 10% or more of total net revenue for the years ended June 30, 2020, 2019 and 2018. The Company had one customer at June 30, 2020 and June 30, 2019, respectively that accounted for more than 10% of accounts receivable, net. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful. Historically, such losses have been within management’s expectations. Single‑source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required. Restricted Cash Restricted cash primarily consists of cash that is temporarily held in bank accounts which are under the control of the lender to the Revolving Credit Facility, certificates of deposit held as guarantees in connection with customer contracts and corporate leases as well as funds held as guarantees for Value‑Added Tax (VAT) obligations in a foreign jurisdiction. Inventories Inventories are stated at the lower of cost (on a first‑in, first‑out basis) or net realizable value. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management. Revenue Recognition The Company adopted ASC Topic 606, Revenue from Contracts with Customers, on July 1, 2018. The Company’s revenue consists of product revenue resulting from the sale of systems, system upgrades and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer, net of any discounts and taxes collected from customers that are remitted to government authorities. The Company’s revenue is primarily derived from sales of CyberKnife and TomoTherapy Systems and services, which include post-contract customer support (“PCS”), installation services, training and other professional services. The majority of the Company's revenue arrangements consists of multiple performance obligations, which can include system, upgrades, installation, training, services, construction, and consumables. For bundled arrangements, the Company accounts for individual products and services separately if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s products are generally sold without a right of return, and the Company’s contracts generally provide a fixed transaction price. The Company may offer incentives in the form of discounts, including volume system discounts, which are included in the contract and used to calculate the final fixed price of the arrangement. These discounts may pertain to all performance obligations in a specific contract or may be allocated to a specific performance obligation. The Company also from time to time offers extended payment terms beyond one year and commissions or other forms of payment to customers. The Company estimates a financing component in transactions with payment terms extending beyond one year. This financing component is recognized as financing income at the time payment is received. The Company applies the practical expedient to not adjust for a significant financing component if the gap between payment and delivery was expected, at the contract inception, to be less than one year. The Company offers customers the opportunity to trade in their older systems for credit towards the purchase of a new system. The Company generally does not provide specif i c trade-in prices or upgrade rights at the time of purchase of the original system. Trade-in or upgrade transactions are based on the then fair value of the system and are separately negotiated taking into consideration circumstances existing at the time of the trade-in or upgrade. Accordingly, trade-ins and upgrades are not considered separate performance obligations in system sales agreements. Traded-in systems generally can be reconditioned and may be resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The stand-alone selling price (“SSP”) of performance obligations is determined based on observable prices at which the Company separately sells the products and services. If the SSP is not directly observable, then the Company will estimate the SSP considering market conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The SSP is generally assessed as a percentage of the list price. The contract consideration allocation is based on the SSP at contract inception. The consideration (net of any discounts) is allocated among separate products and services in a bundle based on their individual SSP. For contract modifications that add additional goods or services or changes pricing, the most recent SSP is used for allocation to the remaining performance obligations. The Company recognizes revenue for certain performance obligations at the point in time when control is transferred, such as delivery of products and upgrades. Service revenue is recognized over the term of the service period as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. Services recognized over a period of time comprise a single stand-ready performance obligation satisfied over time as our customers simultaneously receive and consume benefits from the Company's performance. This performance obligation constitutes a series of services that are substantially the same and provided over time using the same measure of progress. Revenues derived from these arrangements are recognized over time using an output method based upon the passage of time as this provides a faithful depiction of the pattern of transfer of control. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer when the Company expects to generate future economic benefits from the related revenue-generating contracts. The Company capitalizes incremental contract acquisition costs, and amortizes such costs over a five year period, the period which the Company expects to benefit, based on historical service renewal rates, and expectations of future customer renewals. Most of the Company’s contract costs are associated with its internal sales force compensation program and a portion of its employee bonus program. The Company capitalizes and amortizes the incremental costs of obtaining a contract, primarily related to certain bonuses and sales commissions. The capitalized bonuses and sales commissions are amortized over a period of five years commencing upon the initial transfer of control of the system to the customer. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. The amortization of these contract assets is included in cost of sales, research and development, sales and marketing, and general and administrative expenses based on department headcount allocations in the consolidated statements of operations. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. The Company elected to use the practical expedient and expense as incurred commissions related to service renewals and upgrades because the contract term is less than a year. The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms vary from 30 to 90 days, or longer, from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms. Deferred revenue for periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to services being performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for any period presented. Deferred Revenue Deferred revenue primarily consists of unfulfilled obligations from open contracts for which performance has already started including short-shipped items, deferred warranty, training, maintenance services and other unperformed or incomplete performance obligations. Service contracts for maintenance services, in general, are considered month-to-month contracts. Deferred revenue includes deferred warranty expected to be recognized over the remaining warranty period for system already installed. The Company’s balance sheet may include the unbilled receivable for warranty included under the deferred revenue leading to a temporary gross up of the Company’s balance sheet. The invoices for unbilled receivables are issued within period shorter than 12 months. Customer Advances Customer advances represent payments made by customers in advance of product shipment. In general, customer advances are required for a contract to be recognized in our backlog. Property and Equipment Property and equipment are stated at cost and are depreciated using the straight‑line method over the estimated useful lives of the related assets. Leasehold improvements are depreciated on a straight‑line basis over the remaining term of the lease or the estimated useful life of the asset, whichever is shorter. Machinery and equipment are depreciated over five years. Furniture and fixtures are depreciated over four years. Computer and office equipment and computer software are depreciated over three years. Repairs and maintenance costs, which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred. Software Capitalization Costs Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility. Impairment of Long‑Lived Assets The Company reviews long‑lived assets, including intangible assets, equity method investment in the JV, property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable using pretax undiscounted cash flows. Impairment, if any, is measured as the amount by which the carrying value of a long‑lived asset exceeds its fair value. Goodwill and Purchased Intangible Assets Goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. The Company has assessed that it has one operating segment and one reporting unit, and the consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. The Company estimates the fair value of the reporting unit based on the Company’s closing stock price on the trading day closest to the annual review date multiplied by the outstanding shares on that date. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the implied fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required. The Company adopted the new accounting guidance that simplifies the testing for goodwill impairment in the first quarter of fiscal 2020. There was no impairment of goodwill identified in the fiscal years ended June 30, 2020, 2019 and 2018. Purchased intangible assets other than goodwill, including developed technology are amortized on a straight‑line basis over their estimated useful lives unless their lives are determined to be indefinite. Purchased intangible assets are carried at cost, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets which range from approximately one to seven years. Shipping and Handling The Company’s billings for shipping and handling for product shipments to customers are included in cost of products. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of products. Advertising Expenses The Company expenses the costs of advertising and promoting its products and services as incurred. Advertising expenses were approximately $0.2 million, $0.5 million and $0.4 million for the years ended June 30, 2020, 2019 and 2018, respectively, and are included in selling and marketing expense in the consolidated statements of operations. Research and Development Costs Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct compensation, benefits, and other headcount related costs for research and development personnel; costs for materials used in research and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Company’s internal research and development capabilities. Share‑Based Compensation The Company issues stock‑based compensation awards to employees and directors in the form of stock options, restricted stock units (RSUs), performance units (PSUs), market stock units (MSUs) and employee stock purchase plan (ESPP) awards (collectively, awards). The Company measures and recognizes compensation expense for all stock‑based awards based on the awards’ fair value. Share‑based compensation for RSUs and PSUs is measured based on the value of the Company’s common stock on the grant date. The Company uses the Monte‑Carlo simulation model to estimate the fair value of MSUs. Share‑based compensation for employee stock options and ESPP awards are measured on the date of grant using a Black‑Scholes option pricing model. Awards vest either on a graded schedule or in a lump sum. The Company determines the fair value of each award as a single award and recognizes the expense on a straight‑line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. Stock options expire ten years from the date of grant. Share‑based compensation expense for stock options, RSUs, PSUs and the ESPP awards is based on awards ultimately expected to vest, and the expense is recorded net of estimated forfeitures. The Company recognizes expense for MSUs net of estimated forfeitures and does not adjust the expense for subsequent changes in the expected outcome of the market‑based vesting conditions. Loss Contingencies The Company is involved in various lawsuits, claims and proceedings that arise in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews these provisions quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information. Net Income (Loss) Per Common Share Basic and diluted net income (loss) per share is computed by dividing net income (loss) attributable to stockholders by the weighted average number of common shares outstanding during the year. Potentially dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share attributable to stockholders follows (in thousands): Years Ended June 30, 2020 2019 2018 Numerator: Net income (loss) used to compute basic and diluted loss per share $ 3,827 $ (16,430 ) $ (23,899 ) Denominator: Weighted average shares used to compute basic income (loss) per share 89,874 87,465 84,893 Weighted average shares used to compute diluted income (loss) per share 90,623 87,465 84,893 The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSU), Market Stock Units (MSU) and Performance Stock Units (PSU), and the purchase of shares under the Employee Stock Purchase Program (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the 3.75% Convertible Notes due August 2022 (the “3.75% Convertible Notes”), the 3.50% Convertible Senior Notes due February 1, 2018 (the “3.50% Convertible Notes”), the 3.50% Series A Convertible Notes (the “3.50% Series A Convertible Notes”) due February 1, 2018 are included in the calculation of diluted net income per share only if their inclusion is dilutive for periods during which the notes were outstanding. The following table sets forth all potentially dilutive securities excluded from the computation in the table above when their effect would have been anti‑dilutive (in thousands): As of June 30, 2020 2019 2018 Stock options 5,956 5,220 2,684 RSUs, PSUs and MSUs 3,761 3,725 5,159 9,717 8,945 7,843 Outstanding Convertible Notes—Diluted Share Impact The 3.75% Convertible Notes and the 3.50% Series A Convertible Notes have an optional physical (share), cash or combination settlement feature and contain certain conditional conversion features. The 3.50% Series A Convertible Notes were retired in February 2018. Due to the optional cash settlement feature and management’s intent to settle the principal amount thereof in cash, the shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75% Convertible Notes outstanding as of June 30, 2020, totaling approximately 14.9 million shares of our common stock, were not included in the basic and diluted net loss per common share table above. Leases On July 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace the existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized consistent with previous accounting guidance. The Company adopted ASC 842 utilizing the current-period adjustment method added by The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines the lease term by agreement with lessor. As the leases do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Equity Method Investment During the twelve months ended June 30, 2020, the Company adopted a new accounting policy related to equity method investments in connection with its equity investment in CNNC Accuray (Tianjin) Medical Technology Co. Ltd., the Company’s joint venture in China (the “JV”). The equity method investment that the Company holds is equity securities in investees for which the Company has the ability to exercise significant influence over, but lacks a controlling financial interest in the investee. Equity method investment is measured at cost and adjusted for impairment, if any, for the Company’s share of the investee's income or loss and intra-entity profits. The Company recognizes its proportionate share of income or loss from the JV on a one-quarter lag due to the timing of the availability of the JV’s financial records. Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized and such profits would generally be considered realized when the inventory has been sold through to third parties . Equity method goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. Our impairment analysis considers qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative factors include the investee's financial condition and business outlook, industry and sector performance, operational and financing cash flow activities, and other relevant factors affecting the investee. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments, which require judgment and the use of estimates, including discount rates, investee revenue and costs, and comparable market data, among others. Income Taxes The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities. The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, research and development credit carryforwards and other deferred tax assets. The Company records a valuation allowance to reduce its deferred tax assets to the amount the Company believes is more likely than not to be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its domestic and certain foreign net deferred tax assets. The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company’s tax positions in light of legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The Company anticipates that except for $0.01 million in uncertain tax positions tha

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Recent Accounting Pronouncements	Note 2. Recent Accounting Pronouncements Accounting Pronouncement Recently Adopted In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging, which simplifies the application and administration of hedge accounting. The guidance amends the presentation and disclosure requirements and changes how companies assess effectiveness. The guidance is intended to more closely align hedge accounting with companies' risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The guidance was effective for the Company in the first quarter of fiscal 2020 and was adopted on a prospective basis. The adoption of the guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company adopted Topic 842 using the current period adjustment method as of July 1, 2019 and elected the transition option that allows the Company not to restate the comparative periods in its financial statements in the year of adoption. As a result, the Company had not changed previously disclosed amounts or provided additional disclosures for comparative periods. As of July 1, 2019, the right-of-use assets was $30.6 million and the respective lease liability was $34.5 million. The difference between the total right-of-use assets and total lease liabilities recorded as of July 1, 2019 is primarily due to the derecognition of deferred rent liabilities that were included in “Accrued expenses and other current liabilities” and “Other long-term liabilities,” respectively, in the consolidated balance sheet as of June 30, 2019. The Company also elected the package of transition expedients available for expired or existing contracts, which allowed the Company to carryforward its historical assessment of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The Company elected to account for lease and non-lease components in its facility and car leases as a single lease component. As a policy election, for leases that, at commencement date, have a lease term of 12 months or less, the Company records expenses as incurred and does not recognize right-of-use assets and lease liabilities. In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that allows companies to reclassify from Accumulated Other Comprehensive Income to Retained Earnings stranded tax effects resulting from the enactment of the Tax Cuts and Jobs Act (the "Tax Act"). The Company adopted ASU No. 2018‑02 in the first quarter of fiscal year 2020. The adoption of this ASU did not have any impact on the Company’s consolidated financial statements and related disclosures. Accounting Pronouncements Not Yet Effective In June 2016, the FASB issued a new accounting standard to replace the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company will be required to use a forward-looking expected credit loss model for accounts receivable and other financial instruments. The Company will adopt the standard using the modified retrospective transition method on July 1, 2020 beginning of the first quarter of fiscal year 2021. The Company does not currently believe it will have a material impact upon adoption. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) to clarify revenue accounting for collaborative arrangements entered into with customers. The standard is effective for the Company beginning in the first quarter of fiscal year 2021. Early adoption is permitted. The Company is evaluating the impact of adopting this standard to its consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning July 1, 2021 with early adoption permitted. The Company is evaluating the impact of adopting this standard to its consolidated financial statements and related disclosures. In January 2020, the FASB issued ASU 2020-01 Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This standard addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-01, which is effective for the Company in its fiscal year and interim periods beginning on July 1, 2021, to its consolidated financial statements and related disclosures.

Revenue

Revenue	12 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Revenue	Note 3. Revenue Contract Balances The timing of revenue recognition, billings, and cash collections results in trade, unbilled receivables, and deferred revenues on the consolidated balance sheets. The Company may offer longer or extended payments of more than one year for qualified customers in some circumstances. At times, revenue recognition occurs before the billing, resulting in an unbilled receivable, which represents a contract asset. The contract asset is a component of accounts receivable and other assets for the current and non-current portions, respectively. When the Company receives advances or deposits from customers before revenue is recognized, this results in a contract liability. It can take up to two and half years from the time of order to revenue recognition due to the Company’s long sales cycle. Changes in the contract assets and contract liabilities are as follows: June 30, 2020 June 30, 2019 (Dollars in thousands) Amount Amount Assets: Unbilled accounts receivable – current (1) $ 11,739 $ 5,260 Interest receivable – current (2) 493 361 Long-term accounts receivable (3) 3,810 4,116 Interest receivable – non-current (3) 1,342 1,255 Liabilities: Customer advances 22,571 20,395 Deferred revenue – current 83,207 78,332 Deferred revenue – non-current 24,125 26,639 (1) Included in accounts receivable on consolidated balance sheets (2) Included in prepaid expenses and other current assets on consolidated balance sheets (3) Included in other assets on consolidated balance sheets During the years ended June 30, 2020 and June 30, 2019, the Company recognized revenues of $87.7 million and $78.6 million, respectively, which were included in the deferred revenue balances at June 30, 2019 and June 30, 2018, respectively. Remaining Performance Obligations Remaining performance obligations represent deferred revenue from open contracts for which performance has already started and the transaction price from executed non-cancelable contracts for which performance has not yet started. Service contracts in general are considered month-to-month contracts, and the Company has elected the practical expedient to not disclose the unsatisfied performance obligations for contracts with an original expected duration of one year or less. As of June 30, 2020, total remaining performance obligations amounted to $976.3 million. Of this total amount, $78.5 million related to long-term warranty and service, which is expected to be recognized over the remaining warranty period for systems that have been delivered. For systems that have been delivered but not yet installed, management estimates the timing of installation since warranty starts upon installation. The following table represents the Company's remaining performance obligations related to long-term warranty and service as of June 30, 2020 and the estimated revenue expected to be recognized (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products): Fiscal years of revenue recognition (Dollars in thousands) 2021 2022 2023 Thereafter Long-term warranty and service $ 35,223 $ 23,957 $ 9,833 $ 9,470 For the remaining $897.8 million of performance obligations, the Company estimates 21% to 28% will be recognized in the next 12 months, and the remaining portion will be recognized thereafter. The Company’s historical experience indicates that some of its customers will cancel or renegotiate contracts as economic conditions change or when product offerings change during the long sales cycle. Based on historical experience approximately 21% of the Company’s open contracts may never result in revenue due to cancellation. Capitalized Contract Costs The Company capitalizes and amortizes the incremental costs of obtaining a contract, primarily related to certain bonuses and sales commissions. The capitalized bonuses and sales commissions are amortized over a period of five years commencing upon the initial transfer of control of the system to the customer. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. As of June 30, 2020 and 2019, the balance of capitalized costs to obtain a contract was $7.9 million and $8.4 million, respectively. The Company has classified the capitalized costs to obtain a contract as a component of prepaid expenses and other current assets and other assets with respect to the current and non-current portions of capitalized costs, respectively, on the consolidated balance sheets. The Company incurred a $1.2 million and $0.5 million impairment loss for the years ended June 30, 2020 and 2019, respectively. During the years ended June 30, 2020 and 2019 the Company recognized $1.9 million and $2.2 million, respectively, in expense related to the amortization of the capitalized contract costs.

Supplemental Financial Informat

Supplemental Financial Information	12 Months Ended
	Jun. 30, 2020
Supplemental Financial Information Disclosure [Abstract]
Supplemental Financial Information	Note 4. Supplemental Financial Information Consolidated Balance Sheet Accounts receivable, net Accounts receivable, net consisted of the following (in thousands): June 30, 2020 June 30, 2019 Accounts receivable $ 80,128 $ 107,230 Unbilled fees and services 11,739 5,260 91,867 112,490 Less: Allowance for doubtful accounts (1,268 ) (605 ) Accounts receivable, net $ 90,599 $ 111,885 The Company received payment or had credits of $0.4 million, added $1.2 million and wrote off $0.1 million from the allowance for doubtful accounts in fiscal 2020. The Company received payment or had credits of $0.2 million and added $0.6 million to the allowance for doubtful accounts in fiscal 2019. Financing receivables A financing receivable is a contractual right to receive money, on demand or on fixed or determinable dates, that is recognized as an asset in the Company’s balance sheet. The Company’s financing receivables, consisting of its accounts receivable with contractual maturities of more than one year, totaled $3.8 million and $4.3 million at June 30, 2020 and 2019, respectively, and are included in Other Assets in the consolidated balance sheets. The balance in financing receivables related to contractual maturities of more than one year. The Company evaluates the credit quality of an obligor at contract inception and monitors credit quality over the term of the underlying transactions. The Company performs a credit analysis for all new customers and reviews payment history, current order backlog, financial performance of the customers and other variables that augment or mitigate the inherent credit risk of a particular transaction. Such variables include the underlying value and liquidity of the collateral, the essential use of the equipment, the contract term and the inclusion of credit enhancements, such as guarantees, letters of credit or security deposits. The Company classifies accounts as high risk when it considers the financing receivable to be impaired or when management believes there is a significant near‑term risk of non‑payment. The Company performed an assessment of the allowance for credit losses related to its financing receivables. Based upon such assessment, the Company recorded adjustments of $0.8 million and $3.6 million to the allowance for credit losses related to such financing receivables during the years ended June 30, 2020 and 2019, respectively. A summary of the Company’s financing receivables is presented as follows (in thousands): June 30, 2020 June 30, 2019 Gross $ 13,019 $ 13,288 Unearned income (1,774 ) (1,535 ) Allowance for credit loss (4,369 ) (3,582 ) Total, net $ 6,876 $ 8,171 Reported as: Current $ 3,084 $ 3,902 Non-current 3,792 4,269 Total, net $ 6,876 $ 8,171 Actual cash collections may differ from the contracted maturities due to early customer buyouts, refinancing, or defaults. Inventories, net Inventories consisted of the following (in thousands): June 30, 2020 June 30, 2019 Raw materials $ 48,037 $ 40,966 Work-in-process 17,798 18,152 Finished goods 68,539 61,705 Inventories, net $ 134,374 $ 120,823 Property and Equipment, net Property and equipment consisted of the following (in thousands): June 30, 2020 June 30, 2019 Furniture and fixtures $ 1,961 $ 2,728 Computer and office equipment 10,896 11,183 Software 11,606 11,236 Leasehold improvements 26,206 25,741 Machinery and equipment 48,830 45,472 Construction in progress 623 1,658 100,122 98,018 Less: Accumulated depreciation (84,773 ) (80,896 ) Property and equipment, net $ 15,349 $ 17,122 Depreciation and amortization expense related to property and equipment for the years ended June 30, 2020, 2019 and 2018 was $7.3 million, $8.1 million and $9.6 million, respectively. Accumulated Other Comprehensive Income (Loss) The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands): Foreign Currency Items Change in Defined Pension Benefit Obligation Total Balance at June 30, 2018 $ 1,237 $ (144 ) $ 1,093 Other comprehensive loss (247 ) (856 ) (1,103 ) Balance at June 30, 2019 $ 990 $ (1,000 ) $ (10 ) Other comprehensive loss (238 ) (236 ) (474 ) Balance at June 30, 2020 $ 752 $ (1,236 ) $ (484 ) Consolidated Statements of Operations Other expense, net consisted of the following (in thousands): Years Ended June 30, (in thousands) 2020 2019 2018 Interest expense $ (18,080 ) $ (15,084 ) (14,959 ) Foreign currency transaction loss (2,343 ) (665 ) (986 ) Gain on contribution to joint venture 12,964 — — Other (expense) income 759 822 (3,279 ) Total other expense, net $ (6,700 ) $ (14,927 ) $ (19,224 )

Leases

Leases	12 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Leases	Note 5. Leases The Company adopted ASC 842 – Leases using the current period adjustment method beginning on July 1, 2019. Under this approach, the Company did not restate its comparative amounts and recognized a right-of-use asset equal to the present value of the future lease payments. The Company elected to apply the practical expedient that allows for not reassessing: (1) whether any expired or existing contracts are or contain leases, (2) the lease classification for any expired or existing leases and (3) initial direct costs for any expired or existing leases. The practical expedient applied to transition contracts that were previously identified as leases and elected to not recognize right-of-use assets and lease obligations for leases of low value assets. The Company has operating leases for corporate offices and warehouse facilities worldwide. Additionally, the Company leases cars, copy machines and laptops through various operating leases. For some leases the Company has entered into non-cancelable operating lease agreements with various expiration dates through June 2025. Certain lease agreements include options to renew or terminate the lease, which are not reasonably certain to be exercised and therefore are not factored into the determination of lease payments. Operating lease costs for the twelve months ended June 30, 2020 were $9.5 million, not including short-term operating lease costs, which were not material. For the twelve months ended June 30, 2020, cash paid for amounts included in the measurement of operating lease liabilities was approximately $9.5 million. Operating lease liabilities arising from obtaining operating right-of-use assets totaled $5.2 million for the year ended June 30, 2020. Operating lease right-of-use assets and operating lease obligation as of June 30, 2020 represented in the table below (in thousands): Operating Lease Finance Lease (a) Total Operating lease right-of-use asset - initial recognition $ 30,578 $ — $ 30,578 Lease asset added after initial recognition 5,244 10 5,254 Amortization for the year (7,175 ) (2 ) (7,177 ) Balance at June 30, 2020 $ 28,647 $ 8 $ 28,655 Operating lease obligation - initial recognition $ 34,465 $ — $ 34,465 Lease liability added after initial recognition 5,244 10 5,254 Repayment and interest accretion (7,312 ) (2 ) (7,314 ) Balance at June 30, 2020 $ 32,397 $ 8 $ 32,405 Current portion of operating lease obligation $ 8,224 $ 5 $ 8,229 Noncurrent portion of operating lease obligation $ 24,173 $ 3 $ 24,176 (a) Finance lease assets included in property and equipment Maturities of operating lease liabilities as of June 30, 2020 are presented in the table below (in thousands): Year Ending June 30, Amount 2021 $ 9,449 2022 9,130 2023 8,510 2024 5,812 2025 3,005 Total operating lease payments 35,906 Less: imputed interest (3,501 ) Present value of operating lease liabilities $ 32,405 Weighted average remaining lease term (in years) 3.94 Weighted average discount rate 5.30 %

Goodwill and Purchased Intangib

Goodwill and Purchased Intangible Assets	12 Months Ended
	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Purchased Intangible Assets	Note 6. Goodwill and Purchased Intangible Assets Goodwill Goodwill as of June 30, 2020 and 2019 and changes in the carrying amount of goodwill for the respective periods are as follows (in thousands): As of June 30, 2020 2019 Balance at the beginning of the period $ 57,770 $ 57,855 Currency translation (53 ) (85 ) Balance at the end of the period $ 57,717 $ 57,770 In fiscal 2020, the Company performed its annual goodwill impairment test and determined that there was no impairment to goodwill. In addition, d uring the third and fourth quarters of fiscal year 2020, the Company reviewed for possible triggering events due to circumstances surrounding the COVID-19 pandemic and no impairment loss was recorded as a result of such review. Purchased Intangible Assets The Company’s intangible assets associated with purchased patent license are as follows (in thousands): As of June 30, 2020 As of June 30, 2019 Useful Lives Gross Carrying Amount Accumulated Amortization Net Amount Gross Carrying Amount Accumulated Amortization Net Amount (in years) Patent license 2 - 7 $ 1,170 $ (507 ) $ 663 $ 1,000 $ (321 ) $ 679 During fiscal 2017, the Company purchased a patent license with a useful life of seven years. During the quarter ending March 31, 2020 the Company purchased a patent license for $170 thousand with a useful life of two years. Amortization expense related to purchased intangible assets was $0.2 million, $0.1 million and $0.1 million for the years ended June 30, 2020, 2019 and 2018, respectively. The estimated future amortization expense of purchased intangible assets as of June 30, 2020 is as follows (in thousands): Year Ending June 30, Amount 2021 $ 228 2022 185 2023 143 2024 107 $ 663

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Jun. 30, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 7. Derivative Financial Instruments The Company utilizes foreign currency forward contracts with reputable financial institutions to manage its exposure of fluctuations in foreign currency exchange rates on certain intercompany balances and foreign currency denominated cash, customer receivables and liabilities. The Company does not use derivative financial instruments for speculative or trading purposes. These forward contracts are not designated as hedging instruments for accounting purposes. Principal hedged currencies include the Euro, Japanese Yen, Swiss Franc, and U.S. Dollar. The periods of these forward contracts range up to approximately three months and the notional amounts are intended to be consistent with changes in the underlying exposures. The Company intends to exchange foreign currencies for U.S. Dollars at maturity. There were no outstanding foreign currency forward contracts at the end of fiscal years 2020 and 2019. The following table shows the effect of forward contracts not designated as hedging instruments and foreign currency transactions gains and losses, which were included in “Other expense, net” on the consolidated statements of operations in fiscal years (in thousands): Years ended June 30, 2020 2019 2018 Foreign currency exchange gain (loss) on foreign contracts $ 744 $ 17 $ (2,461 ) Foreign currency transactions gain (loss) (3,087 ) (682 ) 1,475

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8. Fair Value Measurements Fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy contains three levels of inputs that may be used to measure fair value, as follows: Level 1— Unadjusted quoted prices that are available in active markets for the identical assets or liabilities at the measurement date. Level 2— Other observable inputs available at the measurement date, other than quoted prices included in Level 1, either directly or indirectly, including: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets in non-active markets; • Inputs other than quoted prices that are observable for the asset or liability; and • Inputs that are derived principally from or corroborated by other observable market data. Level 3— Unobservable inputs that cannot be corroborated by observable market data and require the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management’s estimates of market participant assumptions. The Company had cash of $107.6 million and $76.8 million at June 30, 2020 and June 30, 2019, respectively. Assets and Liabilities That Are Measured at Fair Value on a Nonrecurring Basis The Company’s debt is measured on a non-recurring basis using Level 2 inputs based upon observable inputs of the Company’s underlying stock price and the time value of the conversion option, since an observable quoted price of the 3.75% Convertible Notes (collectively the “Notes”) is not readily available. The Revolving Credit Facility and the Term Loan (collectively, the “Credit Facilities”) are valued at market interest rates, which it considers to be a level 2 fair value measurement. The Company believes that the carrying value of these financial instruments approximate its estimated fair value based on the effective interest rate compared to the current market rate available to the Company. The following table summarizes the carrying value and estimated fair value of Credit Facilities and Notes (in thousands): June 30, 2020 June 30, 2019 Carrying Value Fair Value Carrying Value Fair Value 3.75% Convertible Notes $ 76,398 $ 65,272 $ 72,730 $ 84,227 Term Loan Facility 84,908 84,908 58,849 58,849 Revolving Credit Facility 28,001 28,001 28,265 28,265 Total $ 189,307 $ 178,181 $ 159,844 $ 171,341

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies Long‑term Debt Commitments The Company is required to make semi‑annual interest payments on the 3.75% Convertible Notes, and monthly interest payments on the Revolving Credit Facility and Term Loan. See Note 10, Debt Future minimum long‑term principal and interest on the 3.75% Convertible Notes and Credit Facilities as of June 30, 2020 are as follows (in thousands): Year Ending June 30, Long-Term Debt (1) 2021 $ 14,928 2022 39,669 2023 119,083 2024 60,530 Total $ 234,210 (1) These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company’s consolidated balance sheet. Any conversion, premium, redemption or purchase of the 3.75% Convertible Notes would impact cash payments noted in the preceding table. Purchase Commitments The Company’s purchase commitments and obligations include all open purchase orders and contractual obligations in the ordinary course of business, including commitments with contract manufacturers and suppliers, for which the Company has not received the goods or services and acquisition and licensing of intellectual property. A majority of these purchase obligations are due within a year. Although open purchase orders are considered enforceable and legally binding, the terms generally allows the Company the option to cancel, reschedule, and adjust its requirements based on the Company’s business needs prior to the delivery of goods or performance of services, and hence, have not been included in the table above. Indemnities and Commitments The Company enters into standard indemnification agreements with its landlords and all superior mortgagees and their respective directors, officers’ agents, and employees in the ordinary course of business. Pursuant to these agreements, the Company will indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the landlords, in connection with any loss, accident, injury, or damage by any third‑party with respect to the leased facilities. The term of these indemnification agreements is from the commencement of the lease agreements until termination of the lease agreements. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, historically the Company has not incurred claims or costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has not recorded any liability associated with its indemnification agreements as it is not aware of any pending or threatened actions that represent probable losses as of June 30, 2020. Guarantees As of June 30, 2020, the Company had three bank guarantees totaling approximately $1.0 million related to a bidding process with three customers. As of June 30, 2019, the Company had bank guarantees totaling approximately $0.7 million related to a bidding process with two customers. Royalty The Company has an exclusive license agreement with the Wisconsin Alumni Research Foundation (WARF), to make, use, sell and otherwise distribute products under certain of WARF’s patents anywhere in the world. The Company is required to pay WARF a royalty for each TomoTherapy System sold that includes the licensed technology. The license agreement expires upon expiration of the patents and may be terminated earlier if the Company so elects. The license agreement expired on August 6, 2019 as a result of the expiration of the patent. The Company recorded royalty costs of $0.05 million, $0.6 million and $0.5 million for the years ended June 30, 2020, 2019 and 2018, respectively, which were recorded in cost of revenue or deferred cost of revenue. The Company had no accrued liabilities and approximately $0.2 million at June 30, 2020 and 2019, respectively, related to this agreement. Software License Indemnity Under the terms of the Company’s software license agreements with its customers, the Company agrees that in the event the software sold infringes upon any patent, copyright, trademark, or any other proprietary right of a third‑party, it will indemnify its customer licensees against any loss, expense, or liability from any damages that may be awarded against its customer. The Company includes this infringement indemnification in all of its software license agreements and selected managed services arrangements. In the event the customer cannot use the software or service due to infringement and the Company cannot obtain the right to use, replace or modify the license or service in a commercially feasible manner so that it no longer infringes, then the Company may terminate the license and provide the customer a refund of the fees paid by the customer for the infringing license or service. The Company has not recorded any liability associated with this indemnification, as it is not aware of any pending or threatened actions that represent probable losses as of June 30, 2020. Litigation From time to time, the Company is involved in legal proceedings arising in the ordinary course of its business. The Company records a provision for a loss when it believes that it is both probable that a loss has been incurred and the amount can be reasonably estimated. Currently, management believes the Company does not have any probable and reasonably estimable losses related to any current legal proceedings and claims. Although occasional adverse decisions or settlements may occur, management does not believe that an adverse determination with respect to any of these claims would individually or in the aggregate materially and adversely affect the Company’s financial condition or operating results. Litigation is inherently unpredictable and is subject to significant uncertainties, some of which are beyond the Company’s control. Should any of these estimates and assumptions change or prove to have been incorrect, the Company could incur significant charges related to legal matters that could have a material impact on its results of operations, financial position and cash flows.

Debt

Debt	12 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Debt	Note 10. Debt 3.75% Convertible Senior Notes due July 2022 In August 2017, the Company issued $85.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2022 (the “3.75% Convertible Notes”) under an indenture between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. $53.0 million aggregate principal amount of the 3.75% Convertible Notes were issued to certain holders of the Company’s outstanding 3.50% Convertible Notes and 3.50% Series A Convertible Notes (together, the “Existing Notes”) in exchange for approximately $47.0 million aggregate principal amount of the Existing Notes (the “Exchange”) and $32.0 million aggregate principal amount of the 3.75% Convertible Notes were issued to certain other qualified new investors for cash. The net proceeds of the cash issuance were used to repurchase approximately $28.0 million of Existing Notes (the “Repurchase”). Holders of the 3.75% Convertible Notes may convert their notes at any time on or after April 15, 2022 until the close of the business day immediately preceding the maturity date. Prior to April 15, 2022, holders of the 3.75% Convertible Notes may convert their notes only under certain circumstances. Upon conversion, the Company will have the right to pay cash, or deliver shares of common stock of the Company or a combination thereof, at the Company’s election. The initial conversion rate is 174.8252 shares of the Company’s common stock per $1,000 principal amount (which represents an initial conversion price of approximately $5.72 per share of the Company’s common stock). The conversion rate, and thus the conversion price, is subject to adjustment as further described below. Holders of the 3.75% Convertible Notes who convert their notes in connection with a “make-whole fundamental change,” as defined in the indenture, may be entitled to a make-whole premium in the form of an increase in the conversion rate. Additionally, in the event of a “fundamental change,” as defined in the indenture, holders of the 3.75% Convertible Notes may require the Company to purchase all or a portion of their note at a fundamental change repurchase price equal to 100% of the principal amount of the 3.75% Convertible Notes, plus accrued and unpaid interest, if any, to, but not including, the fundamental change repurchase date. As of June 30, 2020, $85.0 million aggregate principal amount was outstanding. Revolving Credit Facility On June 14, 2017, the Company entered into a credit and security agreement with a lender (the “Credit Agreement”). The Credit Agreement provides the Company with a revolving credit facility in the initial amount of $52.0 million (the “Revolving Credit Facility”). Availability for borrowings under the Revolving Credit Facility is subject to a borrowing base that is calculated as a function of the value of the Company’s eligible accounts receivable and eligible inventory, and the Company is required to maintain a minimum drawn balance of at least 30% of such availability. Interest on the borrowings under the Revolving Credit Facility is payable monthly in arrears at an annual interest rate of reserve-adjusted, 90-day LIBOR plus 4.50% and had initial maturity date of June 14, 2021. In December 2017, concurrently with the Term Loan Agreement (as defined below), the Company entered into an amendment to the Credit Agreement (the “Amendment” and, collectively with the Credit Agreement, the “Amended Credit Agreement”). The Amendment reduced the maximum borrowings under the Revolving Credit Facility to $32.0 million and extended the maturity date of the Revolving Credit Facility to December 15, 2022. In May 2019, the Company amended the Amended Credit Agreement to, among other things, decrease the interest rate from 90-day LIBOR plus 4.50% to 90-day LIBOR plus 3.50% and extend the maturity date to May 30, 2024 and update the calculation of the deferred revolving loan origination fee such that it is based on the amount of time elapsed from the effective date of the May 2019 amendment. The Company accounted for the amendment as a modification of existing debt and deferred an insignificant amount of offering costs on the consolidated balance sheet as of June 30, 2019. The Amended Credit Agreement was further amended in August 2019 to, among other things, revise or add financial covenants, including the fixed charge coverage ratio, minimum net revenue, minimum consolidated cash balance and minimum consolidated domestic cash balance tests. Other significant terms remain unchanged. The Company accounted for the amendment as a modification of existing debt and deferred an insignificant amount of offering costs on the consolidated balance sheet. As of June 30, 2020, approximately $28.0 million of aggregate principal amount was outstanding under the Revolving Credit Facility, and $0.9 million of unamortized debt costs associated with the Revolving Credit Facility was included in other assets on the condensed consolidated balance sheet. Term Loan In December 2017, the Company entered into a credit and security agreement with a lender (the “Term Loan Agreement”). The Term Loan Agreement provides for an initial term loan of $40.0 million with an additional tranche of $20.0 million undrawn and available through December 31, 2018, if specified conditions are met (the “Term Loan”). In connection with the Amendment, the Company used a portion of the net proceeds from the initial advance to repay a portion of the outstanding borrowings under the Revolving Credit Facility. Interest on the Term Loan is payable monthly in arrears at an annual interest rate of 6.75% plus 90-day LIBOR. The Term Loan Agreement matures December 15, 2022 and, if prepaid, has fees equal to 3%, 2%, and 1% of the prepayment amount if such termination occurs within the first year, the second year, and the third year of funding, respectively. The term of the loan is 60 months with interest only for the first 24 months followed by straight-line amortization of principal for the remaining months. In addition, the Company will pay an annual administrative fee of 0.25% and a final payment of 4.0% of the Term Loan amount. In December 2018, the Company drew an additional $5.0 million under the Term Loan Agreement and in connection therewith entered into the second amendment to the Term Loan Agreement (“Amendment 2”) which, among other things, (i) extended the term loan tranche 2 commitment termination date for the remaining $15.0 million unfunded commitment from December 31, 2018 to June 30, 2019; (ii) provided that term loan tranche 2 may be drawn in two separate advances; and (iii) updated the calculation of the prepayment fee such that it is based on the amount of time elapsed from the effective date of Amendment 2. In May 2019, the Company amended the Term Loan Agreement to, among other things, increase the loan tranche 2 commitment by $0.5 million, extend the maturity date to May 30, 2024, decrease the annual interest rate from 6.75% plus 90-day LIBOR to 5.50% plus 90-day LIBOR, and modify the calculation prepayment fee such that it is based on the amount of time elapsed from the effective date of the May 2019 amendment. The Company accounted for the amendment as a modification of existing debt and recorded approximately $ 1.5 million of debt discount costs associated with the amendment against long-term debt on the consolidated balance sheets as of June 30, 2019. In August 2019, the Company amended the Term Loan Agreement to, among other things, increase the loan commitment by $25 million in the form of a new tranche (“Tranche 3”), increase the annual interest rate from 5.50% plus 90-day LIBOR to 6.75% plus 90-day LIBOR, and revise or add financial covenants, including the fixed charge coverage ratio, minimum net revenue, minimum consolidated cash balance and minimum consolidated domestic cash balance tests. Other significant terms remain unchanged. The Company borrowed in full Tranche 3, or $25 million, on the date of the amendment. The Company accounted for the amendment as a modification of existing debt, at the same time, the Company recorded approximately $1.6 million of debt discount costs associated with the amendment against long-term debt. As of June 30, 2020, approximately $89.1 million aggregate principal amount was outstanding. The following table presents the carrying value of all Credit Facilities and 3.75% Convertible Notes (in thousands): Revolving Credit Facility (1) 3.75% Convertible Notes Term Loan Facility Total Carrying amount of equity conversion component $ — $ 14,650 $ — $ 14,650 Principal amount $ 28,001 $ 85,000 $ 89,093 $ 202,094 Unamortized debt costs — (1,922 ) (874 ) (2,796 ) Unamortized debt discount — (6,680 ) (3,311 ) (9,991 ) Net carrying amount $ 28,001 $ 76,398 $ 84,908 $ 189,307 (1) Unamortized debt costs of $0.9 million recorded in other assets on the consolidated balance sheet. A summary of interest expense on the Credit Facilities and Notes is as follows (in thousands): Year ended June 30, 2020 2019 2018 Interest expense related to contractual interest coupon $ 12,373 $ 10,185 $ 9,953 Interest expense related to amortization of debt discount 4,168 3,370 3,377 Interest expense related to amortization of debt issuance costs 1,350 1,529 1,629 Total $ 17,891 $ 15,084 $ 14,959

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Jun. 30, 2020
Stockholders Equity Note [Abstract]
Shareholders' Equity	Note 11. Shareholders’ Equity At June 30, 2020, the Company had 9.7 million shares of common stock reserved for issuance under the stock incentive plans and the employee stock purchase plan.

Stock Incentive Plan and Employ

Stock Incentive Plan and Employee Stock Purchase Plan	12 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Incentive Plan and Employee Stock Purchase Plan	Note 12. Stock Incentive Plan and Employee Stock Purchase Plan As of June 30, 2020, the Company had three outstanding stock incentive plans: the 2016 Equity Incentive Plan, or the 2016 Plan; the 2007 Incentive Award Plan, or the 2007 Plan; and the 1998 Stock Incentive Plan, or the 1998 Plan. The 2016 Plan permits the granting of stock options, stock appreciation rights, restricted stock awards, performance shares, performance units, and restricted stock units, or RSUs. The vesting of RSUs granted under the 2016 Plan are primarily service‑based (over the requisite service period) while the vesting of performance units granted under the 2016 Plan are primarily performance‑based, or PSUs, or market‑based, or MSUs. Only employees of the Company are eligible to receive incentive stock options. Non‑employees may be granted non‑qualified stock options. Stock options granted under the 2016 Plan have an exercise price of at least 100% of the fair market value of the underlying stock on the grant date. The stock options have 10 year contractual terms and generally become exercisable for 25% of the option shares one year from the date of grant and then ratably over the following 36 months. Service‑based RSUs granted under the equity plans generally vest 25% of the share units covered by the grant on each of the first through fourth anniversaries of the date of the grant, subject to the continued service of the grantee through each such date. However, certain of the outstanding RSUs under our equity plans vest 50% upon the first anniversary year of the grant date, and 50% upon the second anniversary year of the grant date. The Board of Directors has the discretion to use different vesting schedules. As of June 30, 2020, the 2007 Plan and the 1998 Plan each continued to remain in effect; however, the Company can no longer grant equity awards under such plans. The following table summarizes the share‑based compensation charges included in the Company’s consolidated statements of operations and comprehensive income (loss) (in thousands): Years ended June 30, 2020 2019 2018 Cost of revenue $ 1,244 $ 1,666 $ 1,866 Research and development 1,457 1,773 2,312 Selling and marketing 1,159 2,081 1,390 General and administrative 4,292 5,081 6,721 Total $ 8,152 $ 10,601 $ 12,289 The amount of capitalized share‑based compensation costs as components of inventory was insignificant at June 30, 2020, 2019 and 2018. Stock Options The fair value of each option is estimated at the date of grant using the Black‑Scholes option pricing formula with the following assumptions: Years Ended June 30, 2020 2019 2018 Risk–free interest rate 1.14% - 1.53% 1.94% - 2.81% 1.98 % Dividend yield — % — % — % Expected term 5.63 - 5.64 5.31 - 5.51 5.25 Expected volatility 47.3% - 48.9% 47.0% - 47.1% 43.9 % Determining Fair Value of Stock Options The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Valuation and Amortization Method —The Company estimates the fair value of its stock options using the Black‑Scholes option‑pricing model. This fair value is then amortized over the requisite service periods of the awards. Expected Term —The Company estimates the expected term of stock option by taking the average of the vesting term and the contractual term of the option, as illustrated by the simplified method. Expected Volatility —The expected volatility is derived from the Company’s historical stock volatility over a period approximately equal to the expected term of the options. Risk ‑Free Interest Rate —The risk ‑free interest rate is based on the U.S. Treasury yield curve on the date of grant. Dividend Yield —The dividend yield assumption is based on the Company’s history and expectation of no dividend payouts. A summary of option activity under the Company’s incentive plan during the fiscal years is presented below (in thousands except per share and term amounts): Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value Balance at June 30, 2017 2,463 $ 6.05 5.42 $ 191 Options granted 795 4.12 Options exercised (109 ) 4.02 Options forfeited/expired (465 ) 7.76 Balance at June 30, 2018 2,684 5.26 6.16 $ 60 Options granted 3,359 4.09 Options exercised (115 ) 4.26 Options forfeited/expired (708 ) 5.51 Balance at June 30, 2019 5,220 4.50 7.97 $ 11 Options granted 2,305 2.64 Options exercised — — Options forfeited/expired (1,569 ) 4.36 Balance at June 30, 2020 5,956 3.82 8.04 $ — Vested or Expected to vest at June 30, 2020 5,222 3.90 7.90 Exercisable at June 30, 2020 2,109 $ 4.73 6.47 The aggregate intrinsic value in the table above represents the total pre‑tax intrinsic value (the difference between the fair value of the Company’s common stock on June 30, 2020 of $2.03 and the exercise price of the options that would have been received by option holders if all options exercisable had been exercised on June 30, 2020. The total intrinsic value of options exercised in the years ended June 30, 2020, 2019 and 2018 was approximately $0 million, $0.1 million and $0.1 million, respectively. During the years ended June 30, 2020, 2019 and 2018, the Company recognized $2.0 million, $1.4 million and $0.6 million, respectively, of share‑based compensation expense for stock options granted to employees. Tax benefits from tax deductions for exercised options and disqualifying dispositions in excess of the deferred tax asset attributable to stock compensation costs for such options are credited to additional paid‑in capital. Upon adoption of ASU 2016-09 on July 1, 2017, the benefits are recognized against income taxes. Realized excess tax benefits related to stock options exercises was zero for each of the years ended June 30, 2020, 2019 and 2018. As of June 30, 2020, there was approximately $6.7 million of unrecognized compensation cost net of estimated forfeitures, related to unvested stock options, which is expected to be recognized over a weighted average period of 2.89 years. The following table summarizes information about outstanding and exercisable options at June 30, 2020 (in thousands, except years and exercise price): Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $2.60 – 2.60 1,815 9.34 $ 2.60 — $ — $2.96 – 4.01 764 7.78 3.60 326 3.99 $4.10 – 4.10 2,543 8.42 4.10 1,007 4.10 $4.23 – 7.70 826 4.29 5.77 768 5.82 $8.01 – 8.01 2 1.00 8.01 2 8.01 $8.89 – 8.89 6 0.83 8.89 6 8.89 Total Outstanding 5,956 8.04 $ 3.82 2,109 $ 4.73 Restricted Stock The following table summarizes the activity of RSUs, PSUs and MSUs (in thousands, except fair value per share): Unvested Restricted Stock Restricted Stock Units Performance Stock Units Market Stock Units Total Number of Shares Underlying Stock Awards Weighted Average Grant Date Fair Value Per Share Unvested at June 30, 2017 3,884 10 1,333 5,227 $ 5.75 Granted 1,529 53 654 2,236 4.40 Vested (1,167 ) — — (1,167 ) 6.24 Cancelled/Forfeited (546 ) — (590 ) (1,136 ) 5.87 Unvested at June 30, 2018 3,700 63 1,397 5,160 5.03 Granted 1,386 — — 1,386 3.68 Vested (1,481 ) (10 ) — (1,491 ) 5.44 Cancelled/Forfeited (521 ) (53 ) (756 ) (1,330 ) 5.10 Unvested at June 30, 2019 3,084 — 641 3,725 4.34 Granted 2,009 419 — 2,428 2.74 Vested (1,579 ) — — (1,579 ) 4.62 Cancelled/Forfeited (343 ) (470 ) (813 ) 3.96 Unvested at June 30, 2020 3,171 419 171 3,761 $ 4.34 As of June 30, 2020, there was approximately $8.7 million of unrecognized compensation cost, net of estimated forfeitures, related to restricted stock, which is expected to be recognized over a weighted average period of 1.76 years. Restricted Stock Units The Company recognized $4.9 million, $7.2 million and $7.8 million of share‑based compensation expense, net of estimated forfeitures, related to RSUs during the years ended June 30, 2020, 2019 and 2018. The weighted average grant date fair value per share of RSUs was $2.74, $3.68 and $4.57 for the years ended June 30, 2020, 2019 and 2018, respectively. The aggregate fair market value of RSUs that vested during the year ended June 30, 2020 was $4.7 million. Performance Stock Units The Compensation Committee approved the grant of 419,000, zero and 53,000 PSUs to select employees of the Company in the years ended June 30, 2020, 2019 and 2018, respectively. Of these PSUs, 10,000 were vested in the year ended June 30, 2019 due to the achievement of the requisite performance targets. No PSUs vested in the years ended June 30, 2020 and June 30, 2018. There was no cancellations of PSUs during the year ended June 30, 2020 and for the years ended June 30, 2019 and 2018, 53,000 and no PSUs were cancelled, respectively. The Company recognized no expense or benefit, a benefit of $0.1 million, and an expense of $0.1 million, of share‑based compensation expense, net of estimated forfeitures, related to PSUs during the years ended June 30, 2020, 2019, and 2018, respectively. Market Stock Units The Compensation Committee approved the performance equity program, referred to as the market stock unit program, or MSU program, in October 2012. The Company’s MSU Program uses the Russell 2000 index as a performance benchmark and requires that the Company’s total stockholder return match or exceed that of the Russell 2000. Based on a sliding scale of how much the Company’s total stockholder return outperforms the Russell 2000 benchmark, the participating executives can earn up to a maximum of 150% of the target number of shares over two measurement periods. The Company uses a Monte‑Carlo simulation to calculate the fair value of the award on the grant date. The Compensation Committee approved the grant of 0.6 million MSUs to select employees of the Company in the year ended June 30, 2018 and none were granted for the years ended June 30, 2020 and 2019. Of these MSUs, no shares vested in the years ending June 30, 2020, 2019 and 2018, respectively, due to the non-achievement of the requisite performance target against the Russell 2000 index while 0.5 million, 0.8 million and 0.6 million MSUs were cancelled in the years ended June 30, 2020, 2019 and 2018, respectively. The Company recognized $0.2 million, $1.0 million and $2.6 million of share‑based compensation expense, net of estimated forfeitures, related to MSUs during the years ended June 30, 2020, 2019 and 2018, respectively. There were no MSUs granted during the years ended June 30, 2020 and 2019. The weighted average grant date fair value per share of MSUs was zero, and $4.11 for the years ended June 30, 2019 and 2018, respectively. As of June 30, 2020, there was approximately $0.1 million of unrecognized compensation cost, net of estimated forfeitures, related to MSUs. Employee Stock Purchase Plan Under the Company’s Amended and Restated 2007 Employee Stock Purchase Plan, or ESPP, qualified employees are permitted to purchase the Company’s common stock at 85% of the lower of the fair market value of the common stock on the commencement date of each offering period or the fair market value on the specified purchase date. The ESPP is deemed compensatory and compensation costs are accounted for under ASC 718, Stock Compensation The Company estimates the fair value of ESPP shares at the date of grant using the Black‑Scholes option pricing model. The weighted average assumptions were as follows: Years Ended June 30, 2020 2019 2018 Risk–free interest rate 0.17% - 1.60% 2.11% - 2.72% 1.07% –2.28% Dividend yield —% —% —% Expected term 0.5 - 1.0 0.5 - 1.0 0.5 – 1.0 Expected volatility 45.46% - 75.21% 30.9% - 60.0% 31.3% – 51.1% The risk‑free rate for the expected term of the ESPP option was based on the U.S. Treasury Constant Maturity rate for each offering period; expected volatility was based on the historical volatility of the Company’s common stock; and the expected term was based upon the offering period of the ESPP. For the years ended June 30, 2020, 2019 and 2018, the Company recognized $1.1 million, $1.1 million and $1.2 million, respectively, of compensation expense related to its ESPP. The Company issued 1.1 million, 0.9 million and 0.9 million shares under the ESPP during fiscal 2020, 2019 and 2018, respectively, at a weighted average price per share of $2.16, $3.31 and $3.62, respectively. As of June 30, 2020, total unrecognized compensation cost related to the ESPP plan was $0.6 million, which the Company expects to recognize over a weighted average period of 0.5 years.

Joint Venture

Joint Venture	12 Months Ended
	Jun. 30, 2020
Equity Method Investments And Joint Ventures [Abstract]
Joint Venture	Note 13. Joint Venture In January 2019, the Company’s wholly-owned subsidiary, Accuray Asia Limited (“Accuray Asia”), entered into an agreement with CNNC High Energy Equipment (Tianjin) Co., Ltd. (the “CIRC Subsidiary”), a wholly-owned subsidiary of China Isotope & Radiation Corporation, to form a joint venture, CNNC Accuray (Tianjin) Medical Technology Co. Ltd. (the “JV”), to manufacture and sell radiation oncology systems in China. In exchange for the 49% equity interest in the JV, the Company, through Accuray Asia, made in-kind capital contributions consisting of two full radiation oncology systems from the Company’s inventory in the quarter ended December 31, 2019. The investment is reported as an Investment in joint venture on the Company’s consolidated balance sheets. The Company recognized a gain of $13.0 million related to the value of the capital contribution to the JV. This gain was recorded as non-operating, other income in the three months ended December 31, 2019. The Company is applying the equity method of accounting to its ownership interest in the JV as the Company has the ability to exercise significant influence over the JV but lacks controlling financial interest and is not the primary beneficiary. The Company recognizes revenue on sales to the JV in the current period, eliminating a portion of profit to the extent goods sold have not been sold through by the JV to an end customer at the end of each reporting period. The Company eliminated $1.8 million of such intra-entity profit from system sales executed during the year ended June 30, 2020 as the transfer of control to the final end user for these systems did not occur before the end of period. The Company recognizes the 49% proportionate share of the JV income or loss on a one-quarter lag due to the timing of the availability of the JV’s financial records. The Company’s consolidated accumulated deficit includes $0.1 million of accumulated losses related to our equity method investment. As of June 30, 2020, the Company had a carrying value of $13.9 million in the JV and owned a 49% interest in the entity. The Company’s proportional share of the underlying equity in net assets of the JV was approximately $10.9 million. The difference represents equity method goodwill. The carrying value of the Company’s investment in the JV was decreased by $1.8 million of intra-entity profit which is not considered in goodwill assessment. The difference of $3.0 million increased by $1.8 million of eliminated profit constitutes equity method goodwill of $4.8 million which is subject to impairment analysis. No impairment was identified as of June 30, 2020.

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 14. Income Taxes Income (loss) before provision for income taxes on the accompanying statements of operations and comprehensive loss included the following components (in thousands): Years Ended June 30, 2020 2019 2018 Domestic $ (1,811 ) $ (23,799 ) $ (30,747 ) Foreign 7,501 9,455 7,726 Total worldwide $ 5,690 $ (14,344 ) $ (23,021 ) The provision for income taxes consisted of the following (in thousands): Years Ended June 30, 2020 2019 2018 Current: Federal $ — $ — $ — State 15 32 63 Foreign 1,495 2,140 785 Total current $ 1,510 $ 2,172 $ 848 Deferred: Federal — — — State — — — Foreign 353 (86 ) 30 Total deferred 353 (86 ) 30 Total provision for income taxes $ 1,863 $ 2,086 $ 878 Income tax payable was $0.8 million, $1.6 million and $1.1 million at June 30, 2020, 2019 and 2018, respectively. A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands): Years Ended June 30, 2020 2019 2018 U.S. federal taxes (benefit): At federal statutory rate $ 1,195 $ (3,012 ) $ (6,446 ) State tax, net of federal benefit 15 32 63 Share-based compensation expense 810 1,128 1,712 Debt extinguishment — — 967 Other non-deductible permanent items 418 486 702 R&D credits (635 ) (877 ) (142 ) Foreign taxes 273 (38 ) (1,295 ) Other (69 ) 58 (228 ) Transition Tax — — 3,348 Tax Cuts and Jobs Act — — 54,072 Global Intangible Low-Taxed Income 1,185 1,924 — Change in valuation allowance (1,329 ) 2,385 (51,875 ) Total $ 1,863 $ 2,086 $ 878 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets were as follows (in thousands): June 30, 2020 2019 Deferred tax assets: Federal and state net operating losses $ 75,615 $ 77,228 Accrued expenses and reserves 4,972 7,497 Lease liability 5,366 — Deferred revenue 5,038 2,897 R&D Credits 22,843 22,108 Share-based compensation expense 1,337 1,327 Capitalized research and development 2,683 3,343 Unicap 2,105 1,953 Fixed assets/intangibles 1,199 1,323 Section 163(j) interest 1,823 1,857 Other 1,290 1,582 Total deferred tax assets 124,271 121,115 Deferred tax liabilities: Contract acquisition costs (977 ) (1,146 ) Right of use assets (4,508 ) — Total deferred tax liabilities (5,485 ) (1,146 ) Valuation allowance (118,300 ) (119,125 ) Net deferred tax assets $ 486 $ 844 As of June 30, 2020, the Company had approximately $322.1 million and $139.1 million in federal and state net operating loss carryforwards, respectively. The federal and state carryforwards expire in varying amounts beginning in 2025 for federal and 2021 for state purposes. In addition, as of June 30, 2020, the Company had federal and state research and development tax credits of approximately $22.0 million and $20.4 million, respectively. If not utilized, the federal research credits will begin to expire in 2021, the California research credits have no expiration date, and the other state research credits will begin to expire in 2021. Under the Internal Revenue Code (“IRC”) Sections 382 and 383, annual use of our net operating loss and research tax credit carryforwards to offset taxable income may be limited based on cumulative changes in ownership. Although ownership changes have occurred in the past, the carryovers should be available for utilization by the Company before they expire, provided the Company generates sufficient future taxable income. There were no equity financings in the current fiscal year that would result in an ownership change under Section 382. The Company will continue to monitor the changes in equity that would affect the tax attributes as reported. Based on the available objective evidence and history of losses, the Company has established a 100% valuation allowance against the combined domestic net deferred tax assets of Accuray and TomoTherapy because of uncertainty surrounding the realization of such deferred tax assets. In December 2017, the Tax Cuts and Jobs Act of 2017 (Tax Act) was signed into law which significantly amends the Internal Revenue Code of 1986, among other things reduces the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, imposes a one-time tax on offshore earnings at reduced rates regardless of whether they are repatriated. The Tax Act did not impact the Company's financial statements due to the Company's historical U.S. losses. In March 2020, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law in the United States. The provisions of the CARES Act did not have a material impact on the Company’s effective tax rate and consolidated financial statements given the Company's full valuation allowance against its net U.S. deferred tax assets. Beginning fiscal year 2019, for U.S. federal tax purposes certain income earned by controlled foreign corporations (“CFCs”) must be included currently in the gross income of the CFC’s U.S. shareholder. The income required to be included in gross income is referred to as global intangible low tax income (“GILTI”) and is defined under IRC Section 951A as the excess of the shareholder’s net CFC tested income over the net deemed tangible income return. The GILTI inclusion amount has been absorbed by net operating losses. The Company has made a policy decision to record GILTI tax as a current-period expense when incurred. The Tax Act also enacted the Base Erosion and Anti-Abuse Tax (“BEAT”). The BEAT minimum tax under IRC Section 59A is applicable to the extent that the BEAT tax amount is greater than the regular corporate tax for a given year. This tax is applicable to companies with prior 3-year average annual gross receipts exceeding $500 million. The Company does not currently meet this threshold since its current average annual gross receipts is less than $500 million. The Company continues to permanently re-invest its $45.2 million undistributed earnings of its foreign subsidiaries outside the U.S. Future repatriation of the Company's foreign earnings are subject to income tax withholdings. Any potential deferred tax liability would net with the Company’s valuation allowance. The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): Years Ended June 30, 2020 2019 2018 Balance at beginning of year $ 16,280 $ 15,299 $ 15,819 Tax positions related to current year: Additions 954 934 823 Tax positions related to prior years: Additions 286 580 — Reductions (524 ) (533 ) (1,343 ) Balance at end of year $ 16,996 $ 16,280 $ 15,299 The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company’s tax positions with respect to legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The reduction in prior year’s tax positions primarily relates to lapses of applicable statutes of limitations. The Company anticipates that except for $0.01 million in uncertain tax positions that may be reduced related to the lapse of various statutes of limitation, there will be no material changes in uncertain tax positions in the next 12 months. As of June 30, 2020, the amount of gross unrecognized tax benefits was $17.0 million of which $16.8 million would not affect income tax expense before consideration of any valuation allowance. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of June 30, 2020 and 2019, the Company had approximately $0.01 million and $0.06 million, respectively, of accrued interest and penalties related to uncertain tax positions. The Company files income tax returns in the United States federal, various states and foreign jurisdictions. Due to tax attributes being carried forward and utilized during open years, the statute of limitations remains open for the U.S. federal jurisdiction and domestic states for tax years from 2000 and forward. The statutes of limitation with respect to the foreign jurisdictions where the Company files income tax returns vary from jurisdiction to jurisdiction and range from 3 to 10 years The Company is also subject to examination of its income tax returns by the Internal Revenue Service (IRS) and other foreign tax authorities, and in some cases the Company has received additional tax assessments which have not been significant .

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Jun. 30, 2020
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plan	Note 15. Employee Benefit Plan The Company’s employee savings and retirement plan is qualified under Section 401(k) of the United States Internal Revenue Code. Employees may make voluntary, tax‑deferred contributions to the 401(k) Plan up to the statutorily prescribed annual limit. The Company makes discretionary matching contributions to the 401(k) Plan on behalf of employees up to the limit determined by the Board of Directors. The Company contributed $2.0 million, $2.1 million and $2.2 million to the 401(k) Plan during the years ended June 30, 2020, 2019 and 2018, respectively.

Defined Benefit Pension Obligat

Defined Benefit Pension Obligation	12 Months Ended
	Jun. 30, 2020
Defined Benefit Pension Obligation Disclosure [Abstract]
Defined Benefit Pension Obligation	Note 16. Defined Benefit Pension Obligation The Company has established a defined benefit pension plan for its employees in its Switzerland subsidiary. The plan provides benefits to employees upon retirement, death or disability. The Company uses June 30 as the year‑end measurement date for this plan. The unfunded liability of $4.5 million was recognized in long‑term other liabilities in the accompanying balance sheet as of June 30, 2020. Actuarial gain of $0.6 million was recognized in other comprehensive loss in fiscal 2020. Obligations and Funded Status The following table presents the funded status of the defined benefit pension plan (in thousands): June 30, 2020 2019 Change in benefit obligation: Benefit obligation—beginning of fiscal year $ 17,577 $ 14,254 Service cost 2,003 1,865 Interest cost 62 128 Plan participants’ contributions 2,886 1,818 Plan amendment 975 — Actuarial (gain)/loss (615 ) 742 Foreign currency changes 545 250 Benefit and expense payments (5,007 ) (1,480 ) Benefit obligation—end of fiscal year $ 18,426 $ 17,577 Change in plan assets: Plan assets—beginning of fiscal year $ 14,228 $ 12,192 Employer contributions 1,327 1,373 Actual return on plan assets 112 122 Plan participants’ contributions 2,885 1,818 Foreign currency changes 413 203 Benefit and expense payments (5,007 ) (1,480 ) Plan assets—end of fiscal year $ 13,958 $ 14,228 Funded status $ (4,468 ) $ (3,349 ) Amounts recognized within the consolidated balance sheets: Assets $ — $ — Long-term other liabilities (4,468 ) (3,349 ) Net amount recognized $ (4,468 ) $ (3,349 ) The following table presents the amounts recognized in accumulated other comprehensive loss (before tax) for the defined benefit pension plan (in thousands): June 30, 2020 2019 Net loss $ (1,000 ) $ (144 ) Total recognized in other comprehensive income (loss) (236 ) (856 ) Accumulated other comprehensive loss $ (1,236 ) $ (1,000 ) The following table presents the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for this defined benefit pension plan where accumulated benefit obligation exceeded the fair value of plan assets (in thousands): June 30, 2020 2019 Projected benefit obligation $ 18,426 $ 17,577 Accumulated benefit obligation $ 16,175 $ 15,506 Fair value of plan assets $ 13,958 $ 14,228 Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Loss The following table shows the components of the Company’s net periodic benefit costs and the other amounts recognized in other comprehensive loss, before tax, related to the Company’s defined benefit pension plan (in thousands): Year ended June 30, 2020 2019 2018 Net Periodic Benefit Costs: Service cost $ 2,003 $ 1,865 $ 1,887 Interest cost 62 128 97 Expected returns on assets (151 ) (170 ) (156 ) Amortization of prior service cost (2 ) (55 ) (44 ) Amortization of net loss — — 11 Settlement charges 178 — — Net periodic benefit costs 2,090 1,768 1,795 Other Amounts Recognized in Other Comprehensive Loss: Net (gain) loss arising during the year (593 ) 801 (901 ) Prior service cost 2 — (105 ) Amortization of prior service cost 1,005 55 44 Amortization of net gain — — (11 ) Effect of settlement (178 ) Total recognized in other comprehensive (gain) loss 236 856 (973 ) Total recognized in net periodic benefit costs and other comprehensive loss $ 2,326 $ 2,624 $ 822 The amounts in accumulated other comprehensive loss that are expected to be recognized as components of net periodic benefit cost during fiscal year 2021 related to the Company’s defined benefit pension plan are as follows (in thousands): 2021 Net loss $ 852 Prior service credit 506 Accumulated other comprehensive loss $ 1,358 Assumptions The assumptions used to determine net periodic benefit cost and to compute the expected long‑term return on assets for the Company’s defined benefit pension plan were as follows: Fiscal Years 2020 2019 2018 Net Periodic Benefit Costs: Discount rate 0.25 % 0.45 % 0.90 % Rate of compensation increase 1.50 % 1.50 % 1.50 % Expected long-term return on assets 1.00 % 1.20 % 1.40 % The assumptions used to measure the benefit obligation for the Company’s defined benefit pension plan were as follows: June 30, 2020 2019 Benefit Obligation: Discount rate 0.25 % 0.45 % Rate of compensation increase 1.50 % 1.50 % Estimated Contributions and Future Benefit Payments The Company made contributions of approximately $1.3 million, $1.4 million and $1.3 million to the defined benefit pension plan during fiscal years 2020, 2019 and 2018 respectively. The Company expects total contributions to the defined benefit pension plan for fiscal year 2021 will be approximately $1.1 million. Estimated future benefit payments expected to be paid by the defined benefit pension plan at June 30, 2020 are as follows (in thousands): Year Ending June 30, Future Benefits 2021 $ 2,344 2022 816 2023 746 2024 688 2025 763 Thereafter 3,189 Total $ 8,546 Plan Assets The plan assets are invested in insurance contracts with Copré Collective Foundation based in Lausanne, Switzerland and Swiss Life Foundation BVG (BVG) insurance company based in Zurich, Switzerland at the end of fiscal year 2020 and 2019, respectively. In fiscal 2020, the risks of death and disability are reinsured with Zurich Life Insurance. The Copré Foundation for Occupational Benefits defines and is responsible for the asset strategy and invests the plan assets for the Company. In 2020, the guaranteed interest rate for mandatory retirement savings is 1.00%. The technical administration and management of the savings account are guaranteed by the Copré Foundation for Occupational Benefits. Insurance benefits due are paid directly to the entitled persons by the Copré Foundation for Occupational Benefits. Accuray International Sàrl has committed itself to pay the annual contributions and costs due under the pension fund regulations. The contract of affiliation between the Company and the Copré C ollective F oundation can be terminated by either side. In the event of a termination, recipients of retirement and survivors’ benefits would remain with the collective foundation. The Company commits itself to transfer its active insured members and recipients of disability benefits to the new employee benefits institution, thus releasing the Copré C ollective F oundation from all obligations.

Segment Disclosure

Segment Disclosure	12 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Segment Disclosure	Note 17. Segment Disclosure The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long‑lived tangible assets by geographic areas. Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Years ended June 30, 2020 2019 2018 Americas $ 128,562 $ 135,683 $ 145,689 Europe, Middle East, India and Africa 119,989 149,095 120,032 Asia Pacific (excluding Japan and India) 61,689 63,793 72,925 Japan 72,688 70,214 66,251 Total $ 382,928 $ 418,785 $ 404,897 Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands): June 30, 2020 June 30, 2019 Americas $ 12,807 $ 13,853 Europe, Middle East, India and Africa 373 575 Asia Pacific (excluding Japan and India) 986 1,419 Japan 1,183 1,275 Total $ 15,349 $ 17,122

Restructuring Charges

Restructuring Charges	12 Months Ended
	Jun. 30, 2020
Restructuring And Related Activities [Abstract]
Restructuring Charges	Note 18. Restructuring Charges On May 27, 2020, the Company informed affected employees of a cost saving initiative designed to reduce operating costs through the elimination of approximately 3 percent of its global workforce. These restructuring charges of $1.1 million were recorded in cost of goods sold and operating expenses in the consolidated statements of operations, of which $0.5 million was paid during fiscal 2020 and $0.6 million is accrued in the consolidated balance sheet as of June 30, 2020. In October 2018, the Company informed affected employees of a cost savings initiative designed to reduce operating costs through the elimination of approximately 5 percent of its global workforce. These restructuring charges of $1.5 million were recorded in cost of goods sold and operating expenses in the consolidated statements of operations, of which $1.0 million was paid during fiscal 2019 and $0.5 million is accrued in the consolidated balance sheet as of June 30, 2019, the remainder was paid in fiscal year 2020. The Company incurred no restructuring charges for the year ended June 30, 2018.

Subsequent Events

Subsequent Events	12 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 19. Subsequent Events On July 3, 2020 the Company further amended the Amended Credit Agreement and Term Loan Agreement which, among other things modified certain financial covenants related to the Fixed Charge Coverage Ratio, minimum consolidated Net Revenue and minimum consolidated cash balance. Other significant terms remained unchanged. In addition, the Company agreed to prepay $10.0 million in principal with respect to the Term Loan as well as an amendment fee of $0.5 million, both of which were paid on July 3, 2020.

Quarterly Financial Data (unaud

Quarterly Financial Data (unaudited)	12 Months Ended
	Jun. 30, 2020
Quarterly Financial Data [Abstract]
Quarterly Financial Data (unaudited)	Note 20. Quarterly Financial Data (unaudited) The following table provides the selected quarterly financial data for fiscal 2020 and 2019 (in thousands, except net income (loss) per share amounts: Quarters ended September 30, 2019 December 31, 2019 March 31, 2020 June 30, 2020 Net revenue $ 89,577 $ 98,826 $ 99,548 $ 94,977 Gross profit $ 32,943 $ 37,900 $ 39,133 $ 39,745 Net Income (loss) $ (9,356 ) $ 10,710 $ 2,625 $ (152 ) Net income (loss) per share - basic $ (0.11 ) $ 0.12 $ 0.03 $ (0.00 ) Net income (loss) per share - diluted $ (0.11 ) $ 0.12 $ 0.03 $ (0.00 ) Weighted average common shares used in computing net income (loss) per share: Basic 88,772 89,517 90,476 90,748 Diluted 88,772 90,279 90,855 90,748 Quarters ended September 30, 2018 December 31, 2018 March 31, 2019 June 30, 2019 Net revenue $ 95,829 $ 102,318 $ 103,221 $ 117,417 Gross profit $ 37,879 $ 38,380 $ 40,466 $ 45,926 Net income loss $ (9,206 ) $ (4,640 ) $ (1,184 ) $ (1,400 ) Net loss per share—basic and diluted $ (0.11 ) $ (0.05 ) $ (0.01 ) $ (0.02 ) Shares used in basic and diluted per share calculation 86,479 87,237 87,962 88,202

The Company and its Significa_2

The Company and its Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in accordance with United States accounting generally accepted accounting principles (“GAAP”), pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”).
Risks and Uncertainties	Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the coronavirus disease (“COVID-19”) pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is highly uncertain and difficult to predict, as the effects of and response to the pandemic are rapidly evolving and new information is regularly coming to light. The Company's customers are diverting resources to treat COVID-19 patients and deferring non-urgent and elective procedures, both of which are likely to impact customers' ability to meet their other financial obligations, including to the Company. Some customers, which include hospitals, major academic medical centers, and other related entities, have incurred significant losses during the COVID-19 pandemic due to reduced patient volume. Furthermore, the Company is also anticipating a global economic slowdown due to disruptions caused by the COVID-19 pandemic, which may result in an incremental adverse impact on revenue, net income and cash flow and may require significant additional expenditures to mitigate such impacts. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The Company’s financial results have also been affected by the COVID-19 pandemic in various ways. The COVID-19 pandemic is adversely impacting the pace at which the backlog converts to revenue in the near-term. This is primarily the result of delays in the timing of deliveries and installations in fiscal 2020 due to timing delays caused by the COVID-19 pandemic, which resulted in a decline to the revenue for the same period. The Company expects that such delays in deliveries and installations will continue into fiscal 2021, which could have a negative impact on the revenue during those periods. As of the date of this Form 10-K, the Company experienced disruptions in the sales and revenue cycle as well as increases in customer defaults, delays in payment and planned installations and service agreements as a result of the effect of the COVID-19 pandemic on the Company’s customers as well as restrictions imposed on travel. The Company also received requests from a few customers to extend payment terms or temporarily suspend service and corresponding payment obligations and while the Company have only received a small number of requests thus far, there can be no guarantee that more customers will not ask for the same if the effects of the COVID-19 pandemic deepen or worsen. As a result, the Company is carefully monitoring the pandemic and the resulting length and depth of the economic impact on our financial condition and results of operations, however, given the uncertainty regarding the spread and potential resurgence of COVID-19 and how long the pandemic will last, the related financial impact cannot be reasonably estimated at this time, although the impacts are expected to continue and may also significantly affect the Company’s business. The Company continues to critically review its liquidity and anticipated capital requirements in light of the significant uncertainty created by the COVID-19 pandemic. Based on the Company’s cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, the Company believes that it will have sufficient cash resources and anticipated cash flows to fund its operations for at least the next 12 months. In addition, the Company is unable to predict with certainty the impact of the COVID-19 pandemic on its ability to maintain compliance with the debt covenants contained in the credit and security agreements related to its Revolving Credit Facility and Term Loan (as such terms are defined in Note 10 below), including financial covenants regarding the fixed charge coverage ratio, minimum net revenue, minimum consolidated cash balance and minimum consolidated domestic cash balance tests. The Company was in compliance with such covenants for the quarter ended June 30, 2020, as amended. Failure to meet the covenant requirements in the future could cause the Company to be in default and the maturity of the related debt could be Subsequent Events
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures at the date of the financial statements. Key estimates and assumptions made by the Company relate to revenue recognition, assessment of recoverability of goodwill and intangible assets, valuation of our equity method investment in the JV, valuation of inventories, share‑based compensation expense, convertible notes, income taxes, allowance for doubtful accounts and loss contingencies. Actual results could differ materially from those estimates.
Foreign Currency	Foreign Currency The Company’s international subsidiaries use their local currencies as their functional currencies. For those subsidiaries, assets and liabilities are translated at exchange rates in effect at the balance sheet date and income and expense accounts at the average exchange rate. Resulting translation adjustments are excluded from the determination of net loss and are recorded in accumulated other comprehensive loss as a separate component of stockholders’ equity. Net foreign currency exchange transaction gains or losses are included as a component of other expense, net, in the Company’s consolidated statements of operations and comprehensive income (loss).
Fair Value Measurements	Fair Value Measurements The carrying values of the Company’s financial instruments including cash equivalents, restricted cash, accounts receivable and accounts payable are approximately equal to their respective fair values due to the relatively short‑term nature of these instruments. Also refer to Note 8, Fair Value Measurements,
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers currency on hand, demand deposits, time deposits, and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents are held in various financial institutions in the United States and internationally.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties The Company’s cash and cash equivalents are mainly deposited with several major financial institutions. At times, deposits in these institutions exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. The Company had no customer that represented 10% or more of total net revenue for the years ended June 30, 2020, 2019 and 2018. The Company had one customer at June 30, 2020 and June 30, 2019, respectively that accounted for more than 10% of accounts receivable, net. The Company performs ongoing credit evaluations of its customers and maintains reserves for potential credit losses. Accounts receivable are deemed past due in accordance with the contractual terms of the agreement. Accounts are charged against the allowance for doubtful accounts once collection efforts are unsuccessful. Historically, such losses have been within management’s expectations. Single‑source suppliers presently provide the Company with several components. In most cases, if a supplier was unable to deliver these components, the Company believes that it would be able to find other sources for these components subject to any regulatory qualifications, if required.
Restricted Cash	Restricted Cash Restricted cash primarily consists of cash that is temporarily held in bank accounts which are under the control of the lender to the Revolving Credit Facility, certificates of deposit held as guarantees in connection with customer contracts and corporate leases as well as funds held as guarantees for Value‑Added Tax (VAT) obligations in a foreign jurisdiction.
Inventories	Inventories Inventories are stated at the lower of cost (on a first‑in, first‑out basis) or net realizable value. Excess and obsolete inventories are written down based on historical sales and forecasted demand, as judged by management.
Revenue Recognition	Revenue Recognition The Company adopted ASC Topic 606, Revenue from Contracts with Customers, on July 1, 2018. The Company’s revenue consists of product revenue resulting from the sale of systems, system upgrades and service revenue. The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. The Company’s revenues are measured based on the consideration specified in the contract with each customer, net of any discounts and taxes collected from customers that are remitted to government authorities. The Company’s revenue is primarily derived from sales of CyberKnife and TomoTherapy Systems and services, which include post-contract customer support (“PCS”), installation services, training and other professional services. The majority of the Company's revenue arrangements consists of multiple performance obligations, which can include system, upgrades, installation, training, services, construction, and consumables. For bundled arrangements, the Company accounts for individual products and services separately if a product or service is separately identifiable from other items in the bundled package and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s products are generally sold without a right of return, and the Company’s contracts generally provide a fixed transaction price. The Company may offer incentives in the form of discounts, including volume system discounts, which are included in the contract and used to calculate the final fixed price of the arrangement. These discounts may pertain to all performance obligations in a specific contract or may be allocated to a specific performance obligation. The Company also from time to time offers extended payment terms beyond one year and commissions or other forms of payment to customers. The Company estimates a financing component in transactions with payment terms extending beyond one year. This financing component is recognized as financing income at the time payment is received. The Company applies the practical expedient to not adjust for a significant financing component if the gap between payment and delivery was expected, at the contract inception, to be less than one year. The Company offers customers the opportunity to trade in their older systems for credit towards the purchase of a new system. The Company generally does not provide specif i c trade-in prices or upgrade rights at the time of purchase of the original system. Trade-in or upgrade transactions are based on the then fair value of the system and are separately negotiated taking into consideration circumstances existing at the time of the trade-in or upgrade. Accordingly, trade-ins and upgrades are not considered separate performance obligations in system sales agreements. Traded-in systems generally can be reconditioned and may be resold. The Company accounts for the fair value of the traded-in system in the total consideration in the arrangement by including the net realizable value of the traded-in system less a normal profit margin. The stand-alone selling price (“SSP”) of performance obligations is determined based on observable prices at which the Company separately sells the products and services. If the SSP is not directly observable, then the Company will estimate the SSP considering market conditions, entity-specific factors, and information about the customer or class of customer that is reasonably available. The SSP is generally assessed as a percentage of the list price. The contract consideration allocation is based on the SSP at contract inception. The consideration (net of any discounts) is allocated among separate products and services in a bundle based on their individual SSP. For contract modifications that add additional goods or services or changes pricing, the most recent SSP is used for allocation to the remaining performance obligations. The Company recognizes revenue for certain performance obligations at the point in time when control is transferred, such as delivery of products and upgrades. Service revenue is recognized over the term of the service period as the customer benefits from the services throughout the service period. Revenue related to services performed on a time-and-materials basis is recognized when performed. Services recognized over a period of time comprise a single stand-ready performance obligation satisfied over time as our customers simultaneously receive and consume benefits from the Company's performance. This performance obligation constitutes a series of services that are substantially the same and provided over time using the same measure of progress. Revenues derived from these arrangements are recognized over time using an output method based upon the passage of time as this provides a faithful depiction of the pattern of transfer of control. The Company recognizes an asset for the incremental costs of obtaining a contract with a customer when the Company expects to generate future economic benefits from the related revenue-generating contracts. The Company capitalizes incremental contract acquisition costs, and amortizes such costs over a five year period, the period which the Company expects to benefit, based on historical service renewal rates, and expectations of future customer renewals. Most of the Company’s contract costs are associated with its internal sales force compensation program and a portion of its employee bonus program. The Company capitalizes and amortizes the incremental costs of obtaining a contract, primarily related to certain bonuses and sales commissions. The capitalized bonuses and sales commissions are amortized over a period of five years commencing upon the initial transfer of control of the system to the customer. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. The amortization of these contract assets is included in cost of sales, research and development, sales and marketing, and general and administrative expenses based on department headcount allocations in the consolidated statements of operations. The pattern of amortization is commensurate with the pattern of transfer of control of the performance obligations to the customer. The Company elected to use the practical expedient and expense as incurred commissions related to service renewals and upgrades because the contract term is less than a year. The Company invoices its customers based on the billing schedules in its sales arrangements. Payment terms vary from 30 to 90 days, or longer, from the date of invoice. Contract assets for the periods presented primarily represent the difference between the revenue that was recognized based on the relative standalone selling price of the related performance obligations satisfied and the contractual billing terms. Deferred revenue for periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to services being performed. The associated deferred revenue is generally recognized over the term of the service period. The Company did not have any significant impairment losses on its contract assets for any period presented.
Deferred Revenue	Deferred Revenue Deferred revenue primarily consists of unfulfilled obligations from open contracts for which performance has already started including short-shipped items, deferred warranty, training, maintenance services and other unperformed or incomplete performance obligations. Service contracts for maintenance services, in general, are considered month-to-month contracts. Deferred revenue includes deferred warranty expected to be recognized over the remaining warranty period for system already installed. The Company’s balance sheet may include the unbilled receivable for warranty included under the deferred revenue leading to a temporary gross up of the Company’s balance sheet. The invoices for unbilled receivables are issued within period shorter than 12 months.
Customers Advances	Customer Advances Customer advances represent payments made by customers in advance of product shipment. In general, customer advances are required for a contract to be recognized in our backlog.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are depreciated using the straight‑line method over the estimated useful lives of the related assets. Leasehold improvements are depreciated on a straight‑line basis over the remaining term of the lease or the estimated useful life of the asset, whichever is shorter. Machinery and equipment are depreciated over five years. Furniture and fixtures are depreciated over four years. Computer and office equipment and computer software are depreciated over three years. Repairs and maintenance costs, which are not considered improvements and do not extend the useful life of the property and equipment, are expensed as incurred.
Software Capitalization Costs	Software Capitalization Costs Costs for the development of new software products and substantial enhancements to existing software products are expensed as incurred until technological feasibility has been established, at which time any additional costs would be capitalized. No costs associated with the development of software have been capitalized as the Company believes its current software development process is essentially completed concurrent with the establishment of technological feasibility.
Impairment of Long-Lived Assets	Impairment of Long‑Lived Assets The Company reviews long‑lived assets, including intangible assets, equity method investment in the JV, property and equipment, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable using pretax undiscounted cash flows. Impairment, if any, is measured as the amount by which the carrying value of a long‑lived asset exceeds its fair value.
Goodwill and Purchased Intangible Assets	Goodwill and Purchased Intangible Assets Goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. The Company has assessed that it has one operating segment and one reporting unit, and the consolidated net assets, including existing goodwill and other intangible assets, are considered to be the carrying value of the reporting unit. The Company estimates the fair value of the reporting unit based on the Company’s closing stock price on the trading day closest to the annual review date multiplied by the outstanding shares on that date. If the carrying value of the reporting unit is in excess of its fair value, an impairment may exist, and the Company must perform the second step of the analysis, in which the implied fair value of the goodwill is compared to its carrying value to determine the impairment charge, if any. If the estimated fair value of the reporting unit exceeds the carrying value of the reporting unit, goodwill is not impaired and no further analysis is required. The Company adopted the new accounting guidance that simplifies the testing for goodwill impairment in the first quarter of fiscal 2020. There was no impairment of goodwill identified in the fiscal years ended June 30, 2020, 2019 and 2018. Purchased intangible assets other than goodwill, including developed technology are amortized on a straight‑line basis over their estimated useful lives unless their lives are determined to be indefinite. Purchased intangible assets are carried at cost, less accumulated amortization. Amortization is computed over the estimated useful lives of the respective assets which range from approximately one to seven years.
Shipping and Handling	Shipping and Handling The Company’s billings for shipping and handling for product shipments to customers are included in cost of products. Shipping and handling costs incurred for inventory purchases are capitalized in inventory and expensed in cost of products.
Advertising Expenses	Advertising Expenses The Company expenses the costs of advertising and promoting its products and services as incurred. Advertising expenses were approximately $0.2 million, $0.5 million and $0.4 million for the years ended June 30, 2020, 2019 and 2018, respectively, and are included in selling and marketing expense in the consolidated statements of operations.
Research and Development Costs	Research and Development Costs Costs related to research, design and development of products are charged to research and development expense as incurred. These costs include direct compensation, benefits, and other headcount related costs for research and development personnel; costs for materials used in research and development activities; costs for outside services and allocated portions of facilities and other corporate costs. The Company has entered into research and clinical study arrangements with selected hospitals, cancer treatment centers, academic institutions and research institutions worldwide. These agreements support the Company’s internal research and development capabilities.
Share-Based Compensation	Share‑Based Compensation The Company issues stock‑based compensation awards to employees and directors in the form of stock options, restricted stock units (RSUs), performance units (PSUs), market stock units (MSUs) and employee stock purchase plan (ESPP) awards (collectively, awards). The Company measures and recognizes compensation expense for all stock‑based awards based on the awards’ fair value. Share‑based compensation for RSUs and PSUs is measured based on the value of the Company’s common stock on the grant date. The Company uses the Monte‑Carlo simulation model to estimate the fair value of MSUs. Share‑based compensation for employee stock options and ESPP awards are measured on the date of grant using a Black‑Scholes option pricing model. Awards vest either on a graded schedule or in a lump sum. The Company determines the fair value of each award as a single award and recognizes the expense on a straight‑line basis over the service period of the award, which is generally the vesting period. The exercise price of stock options granted is equal to the fair market value of the Company’s common stock on the date of grant. Stock options expire ten years from the date of grant. Share‑based compensation expense for stock options, RSUs, PSUs and the ESPP awards is based on awards ultimately expected to vest, and the expense is recorded net of estimated forfeitures. The Company recognizes expense for MSUs net of estimated forfeitures and does not adjust the expense for subsequent changes in the expected outcome of the market‑based vesting conditions.
Loss Contingencies	Loss Contingencies The Company is involved in various lawsuits, claims and proceedings that arise in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. The Company reviews these provisions quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel, and updated information.
Net Income (Loss) Per Common Share	Net Income (Loss) Per Common Share Basic and diluted net income (loss) per share is computed by dividing net income (loss) attributable to stockholders by the weighted average number of common shares outstanding during the year. Potentially dilutive outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for loss periods presented because including them would have been antidilutive. A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share attributable to stockholders follows (in thousands): Years Ended June 30, 2020 2019 2018 Numerator: Net income (loss) used to compute basic and diluted loss per share $ 3,827 $ (16,430 ) $ (23,899 ) Denominator: Weighted average shares used to compute basic income (loss) per share 89,874 87,465 84,893 Weighted average shares used to compute diluted income (loss) per share 90,623 87,465 84,893 The potentially dilutive shares of the Company’s common stock resulting from the assumed exercise of outstanding stock options, the vesting of Restricted Stock Units (RSU), Market Stock Units (MSU) and Performance Stock Units (PSU), and the purchase of shares under the Employee Stock Purchase Program (ESPP), as determined under the treasury stock method, are excluded from the computation of diluted net income (loss) per share when their effect would have been anti‑dilutive. Additionally, the 3.75% Convertible Notes due August 2022 (the “3.75% Convertible Notes”), the 3.50% Convertible Senior Notes due February 1, 2018 (the “3.50% Convertible Notes”), the 3.50% Series A Convertible Notes (the “3.50% Series A Convertible Notes”) due February 1, 2018 are included in the calculation of diluted net income per share only if their inclusion is dilutive for periods during which the notes were outstanding. The following table sets forth all potentially dilutive securities excluded from the computation in the table above when their effect would have been anti‑dilutive (in thousands): As of June 30, 2020 2019 2018 Stock options 5,956 5,220 2,684 RSUs, PSUs and MSUs 3,761 3,725 5,159 9,717 8,945 7,843 Outstanding Convertible Notes—Diluted Share Impact The 3.75% Convertible Notes and the 3.50% Series A Convertible Notes have an optional physical (share), cash or combination settlement feature and contain certain conditional conversion features. The 3.50% Series A Convertible Notes were retired in February 2018. Due to the optional cash settlement feature and management’s intent to settle the principal amount thereof in cash, the shares of common stock issuable upon conversion of the outstanding principal amount of the 3.75% Convertible Notes outstanding as of June 30, 2020, totaling approximately 14.9 million shares of our common stock, were not included in the basic and diluted net loss per common share table above.
Leases	Leases On July 1, 2019, the Company adopted Accounting Standards Codification Topic 842, “Leases” (“ASC 842”) to replace the existing lease accounting guidance. This pronouncement is intended to provide enhanced transparency and comparability by requiring lessees to record right-of-use assets and corresponding lease liabilities on the balance sheet for most leases. Expenses associated with leases will continue to be recognized consistent with previous accounting guidance. The Company adopted ASC 842 utilizing the current-period adjustment method added by The Company is the lessee in a lease contract when the Company obtains the right to use the asset. Operating leases are included in the line items right-of-use asset, lease obligation, current, and lease obligation, long-term in the consolidated balance sheet. Right-of-use asset represents the Company’s right to use an underlying asset for the lease term and lease obligations represent the Company’s obligations to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the lease term in the consolidated statement of operations. The Company determines the lease term by agreement with lessor. As the leases do not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.
Equity Method Investment	Equity Method Investment During the twelve months ended June 30, 2020, the Company adopted a new accounting policy related to equity method investments in connection with its equity investment in CNNC Accuray (Tianjin) Medical Technology Co. Ltd., the Company’s joint venture in China (the “JV”). The equity method investment that the Company holds is equity securities in investees for which the Company has the ability to exercise significant influence over, but lacks a controlling financial interest in the investee. Equity method investment is measured at cost and adjusted for impairment, if any, for the Company’s share of the investee's income or loss and intra-entity profits. The Company recognizes its proportionate share of income or loss from the JV on a one-quarter lag due to the timing of the availability of the JV’s financial records. Profit earned by the Company from the JV is eliminated through cost of goods sold until it is realized and such profits would generally be considered realized when the inventory has been sold through to third parties . Equity method goodwill is not amortized, but is evaluated for impairment on an annual basis and when impairment indicators are present. Our impairment analysis considers qualitative and quantitative factors that may have a significant impact on the investee's fair value. Qualitative factors include the investee's financial condition and business outlook, industry and sector performance, operational and financing cash flow activities, and other relevant factors affecting the investee. When indicators of impairment exist, we prepare quantitative assessments of the fair value of our non-marketable equity investments, which require judgment and the use of estimates, including discount rates, investee revenue and costs, and comparable market data, among others.
Income Taxes	Income Taxes The Company is required to estimate its income taxes in each of the tax jurisdictions in which it operates prior to the completion and filing of tax returns for such periods. This process involves estimating actual current tax expense together with assessing temporary differences in the treatment of items for tax purposes versus financial accounting purposes that may create net deferred tax assets and liabilities. The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax bases of the Company’s assets and liabilities and their financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses, research and development credit carryforwards and other deferred tax assets. The Company records a valuation allowance to reduce its deferred tax assets to the amount the Company believes is more likely than not to be realized. Because of the uncertainty of the realization of the deferred tax assets, the Company has recorded a full valuation allowance against its domestic and certain foreign net deferred tax assets. The calculation of unrecognized tax benefits involves dealing with uncertainties in the application of complex global tax regulations. Management regularly assesses the Company’s tax positions in light of legislative, bilateral tax treaty, regulatory and judicial developments in the countries in which the Company does business. The Company anticipates that except for $0.01 million in uncertain tax positions that may be reduced related to the lapse of various statutes of limitation, there will be no material changes in uncertain tax positions in the next 12 months.
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The components of comprehensive income (loss) consist of net income (loss), changes in foreign currency exchange rate translation and net changes related to a defined benefit pension plan. The changes in foreign currency exchange rate translation and net changes related to the defined benefit pension plan are excluded from earnings and reported as a component of stockholders’ equity. The foreign currency translation adjustment results from those subsidiaries not using the United States dollar as their functional currency since the majority of their economic activities are primarily denominated in their applicable local currency. Accordingly, all assets and liabilities related to these operations are translated at the current exchange rates at the end of each period. The resulting cumulative translation adjustments are recorded directly to the accumulated other comprehensive loss account in stockholders’ equity. Revenues and expenses are translated at average exchange rates in effect during the period.

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements (Policies)	12 Months Ended
	Jun. 30, 2020
Accounting Pronouncement Recently Adopted
Accounting Pronouncements	Accounting Pronouncement Recently Adopted In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging, which simplifies the application and administration of hedge accounting. The guidance amends the presentation and disclosure requirements and changes how companies assess effectiveness. The guidance is intended to more closely align hedge accounting with companies' risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The guidance was effective for the Company in the first quarter of fiscal 2020 and was adopted on a prospective basis. The adoption of the guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)”, which requires lessees to recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use assets. The Company adopted Topic 842 using the current period adjustment method as of July 1, 2019 and elected the transition option that allows the Company not to restate the comparative periods in its financial statements in the year of adoption. As a result, the Company had not changed previously disclosed amounts or provided additional disclosures for comparative periods. As of July 1, 2019, the right-of-use assets was $30.6 million and the respective lease liability was $34.5 million. The difference between the total right-of-use assets and total lease liabilities recorded as of July 1, 2019 is primarily due to the derecognition of deferred rent liabilities that were included in “Accrued expenses and other current liabilities” and “Other long-term liabilities,” respectively, in the consolidated balance sheet as of June 30, 2019. The Company also elected the package of transition expedients available for expired or existing contracts, which allowed the Company to carryforward its historical assessment of (1) whether contracts are or contain leases, (2) lease classification and (3) initial direct costs. The Company elected to account for lease and non-lease components in its facility and car leases as a single lease component. As a policy election, for leases that, at commencement date, have a lease term of 12 months or less, the Company records expenses as incurred and does not recognize right-of-use assets and lease liabilities. In February 2018, the FASB issued ASU No. 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, that allows companies to reclassify from Accumulated Other Comprehensive Income to Retained Earnings stranded tax effects resulting from the enactment of the Tax Cuts and Jobs Act (the "Tax Act"). The Company adopted ASU No. 2018‑02 in the first quarter of fiscal year 2020. The adoption of this ASU did not have any impact on the Company’s consolidated financial statements and related disclosures.
Accounting Pronouncements Not Yet Effective
Accounting Pronouncements	Accounting Pronouncements Not Yet Effective In June 2016, the FASB issued a new accounting standard to replace the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company will be required to use a forward-looking expected credit loss model for accounts receivable and other financial instruments. The Company will adopt the standard using the modified retrospective transition method on July 1, 2020 beginning of the first quarter of fiscal year 2021. The Company does not currently believe it will have a material impact upon adoption. In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808) to clarify revenue accounting for collaborative arrangements entered into with customers. The standard is effective for the Company beginning in the first quarter of fiscal year 2021. Early adoption is permitted. The Company is evaluating the impact of adopting this standard to its consolidated financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ASU 2019-12 is effective for the Company beginning July 1, 2021 with early adoption permitted. The Company is evaluating the impact of adopting this standard to its consolidated financial statements and related disclosures. In January 2020, the FASB issued ASU 2020-01 Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) - Clarifying the Interactions between Topic 321, Topic 323, and Topic 815. This standard addresses accounting for the transition into and out of the equity method and provides clarification of the interaction of rules for equity securities, the equity method of accounting, and forward contracts and purchase options on certain types of securities. This standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2020-01, which is effective for the Company in its fiscal year and interim periods beginning on July 1, 2021, to its consolidated financial statements and related disclosures.

The Company and its Significa_3

The Company and its Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share	A reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per share attributable to stockholders follows (in thousands): Years Ended June 30, 2020 2019 2018 Numerator: Net income (loss) used to compute basic and diluted loss per share $ 3,827 $ (16,430 ) $ (23,899 ) Denominator: Weighted average shares used to compute basic income (loss) per share 89,874 87,465 84,893 Weighted average shares used to compute diluted income (loss) per share 90,623 87,465 84,893
Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per common share	The following table sets forth all potentially dilutive securities excluded from the computation in the table above when their effect would have been anti‑dilutive (in thousands): As of June 30, 2020 2019 2018 Stock options 5,956 5,220 2,684 RSUs, PSUs and MSUs 3,761 3,725 5,159 9,717 8,945 7,843

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Jun. 30, 2020
Revenue From Contract With Customer [Abstract]
Summary of Contract with Customer, Asset and Liability	Changes in the contract assets and contract liabilities are as follows: June 30, 2020 June 30, 2019 (Dollars in thousands) Amount Amount Assets: Unbilled accounts receivable – current (1) $ 11,739 $ 5,260 Interest receivable – current (2) 493 361 Long-term accounts receivable (3) 3,810 4,116 Interest receivable – non-current (3) 1,342 1,255 Liabilities: Customer advances 22,571 20,395 Deferred revenue – current 83,207 78,332 Deferred revenue – non-current 24,125 26,639 (1) Included in accounts receivable on consolidated balance sheets (2) Included in prepaid expenses and other current assets on consolidated balance sheets (3) Included in other assets on consolidated balance sheets
Schedule of Remaining Performance Obligations related to Warranty	The following table represents the Company's remaining performance obligations related to long-term warranty and service as of June 30, 2020 and the estimated revenue expected to be recognized (the time bands reflect management’s best estimate of when the Company will transfer control to the customer and may change based on timing of shipment, readiness of customers’ facilities for installation, installation requirements, and availability of products): Fiscal years of revenue recognition (Dollars in thousands) 2021 2022 2023 Thereafter Long-term warranty and service $ 35,223 $ 23,957 $ 9,833 $ 9,470

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)	12 Months Ended
	Jun. 30, 2020
Supplemental Financial Information Disclosure [Abstract]
Schedule of accounts receivable, net	Accounts receivable, net consisted of the following (in thousands): June 30, 2020 June 30, 2019 Accounts receivable $ 80,128 $ 107,230 Unbilled fees and services 11,739 5,260 91,867 112,490 Less: Allowance for doubtful accounts (1,268 ) (605 ) Accounts receivable, net $ 90,599 $ 111,885
Schedule of financing receivables	A summary of the Company’s financing receivables is presented as follows (in thousands): June 30, 2020 June 30, 2019 Gross $ 13,019 $ 13,288 Unearned income (1,774 ) (1,535 ) Allowance for credit loss (4,369 ) (3,582 ) Total, net $ 6,876 $ 8,171 Reported as: Current $ 3,084 $ 3,902 Non-current 3,792 4,269 Total, net $ 6,876 $ 8,171
Schedule of inventories, net	Inventories consisted of the following (in thousands): June 30, 2020 June 30, 2019 Raw materials $ 48,037 $ 40,966 Work-in-process 17,798 18,152 Finished goods 68,539 61,705 Inventories, net $ 134,374 $ 120,823
Schedule of property and equipment, net	Property and equipment consisted of the following (in thousands): June 30, 2020 June 30, 2019 Furniture and fixtures $ 1,961 $ 2,728 Computer and office equipment 10,896 11,183 Software 11,606 11,236 Leasehold improvements 26,206 25,741 Machinery and equipment 48,830 45,472 Construction in progress 623 1,658 100,122 98,018 Less: Accumulated depreciation (84,773 ) (80,896 ) Property and equipment, net $ 15,349 $ 17,122
Schedule of components of accumulated other comprehensive income (loss)	The following table summarizes the changes in accumulated other comprehensive income (loss) by component (in thousands): Foreign Currency Items Change in Defined Pension Benefit Obligation Total Balance at June 30, 2018 $ 1,237 $ (144 ) $ 1,093 Other comprehensive loss (247 ) (856 ) (1,103 ) Balance at June 30, 2019 $ 990 $ (1,000 ) $ (10 ) Other comprehensive loss (238 ) (236 ) (474 ) Balance at June 30, 2020 $ 752 $ (1,236 ) $ (484 )
Schedule of consolidated statement of operations	Other expense, net consisted of the following (in thousands): Years Ended June 30, (in thousands) 2020 2019 2018 Interest expense $ (18,080 ) $ (15,084 ) (14,959 ) Foreign currency transaction loss (2,343 ) (665 ) (986 ) Gain on contribution to joint venture 12,964 — — Other (expense) income 759 822 (3,279 ) Total other expense, net $ (6,700 ) $ (14,927 ) $ (19,224 )

Leases (Tables)

Leases (Tables)	12 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligation	Operating lease right-of-use assets and operating lease obligation as of June 30, 2020 represented in the table below (in thousands): Operating Lease Finance Lease (a) Total Operating lease right-of-use asset - initial recognition $ 30,578 $ — $ 30,578 Lease asset added after initial recognition 5,244 10 5,254 Amortization for the year (7,175 ) (2 ) (7,177 ) Balance at June 30, 2020 $ 28,647 $ 8 $ 28,655 Operating lease obligation - initial recognition $ 34,465 $ — $ 34,465 Lease liability added after initial recognition 5,244 10 5,254 Repayment and interest accretion (7,312 ) (2 ) (7,314 ) Balance at June 30, 2020 $ 32,397 $ 8 $ 32,405 Current portion of operating lease obligation $ 8,224 $ 5 $ 8,229 Noncurrent portion of operating lease obligation $ 24,173 $ 3 $ 24,176 (a) Finance lease assets included in property and equipment
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of June 30, 2020 are presented in the table below (in thousands): Year Ending June 30, Amount 2021 $ 9,449 2022 9,130 2023 8,510 2024 5,812 2025 3,005 Total operating lease payments 35,906 Less: imputed interest (3,501 ) Present value of operating lease liabilities $ 32,405 Weighted average remaining lease term (in years) 3.94 Weighted average discount rate 5.30 %

Goodwill and Purchased Intang_2

Goodwill and Purchased Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Schedule of goodwill and changes in the carrying amount of goodwill	Goodwill as of June 30, 2020 and 2019 and changes in the carrying amount of goodwill for the respective periods are as follows (in thousands): As of June 30, 2020 2019 Balance at the beginning of the period $ 57,770 $ 57,855 Currency translation (53 ) (85 ) Balance at the end of the period $ 57,717 $ 57,770
Schedule of intangible assets associated with purchased patent license	The Company’s intangible assets associated with purchased patent license are as follows (in thousands): As of June 30, 2020 As of June 30, 2019 Useful Lives Gross Carrying Amount Accumulated Amortization Net Amount Gross Carrying Amount Accumulated Amortization Net Amount (in years) Patent license 2 - 7 $ 1,170 $ (507 ) $ 663 $ 1,000 $ (321 ) $ 679
Schedule of estimated future amortization expense of purchased intangible assets	The estimated future amortization expense of purchased intangible assets as of June 30, 2020 is as follows (in thousands): Year Ending June 30, Amount 2021 $ 228 2022 185 2023 143 2024 107 $ 663

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Jun. 30, 2020
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Schedule of effect of forward contracts not designated as hedging instruments and foreign currency transactions gains and losses	The following table shows the effect of forward contracts not designated as hedging instruments and foreign currency transactions gains and losses, which were included in “Other expense, net” on the consolidated statements of operations in fiscal years (in thousands): Years ended June 30, 2020 2019 2018 Foreign currency exchange gain (loss) on foreign contracts $ 744 $ 17 $ (2,461 ) Foreign currency transactions gain (loss) (3,087 ) (682 ) 1,475

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Summary of carrying values and estimated fair values of short-term and long-term debt	The following table summarizes the carrying value and estimated fair value of Credit Facilities and Notes (in thousands): June 30, 2020 June 30, 2019 Carrying Value Fair Value Carrying Value Fair Value 3.75% Convertible Notes $ 76,398 $ 65,272 $ 72,730 $ 84,227 Term Loan Facility 84,908 84,908 58,849 58,849 Revolving Credit Facility 28,001 28,001 28,265 28,265 Total $ 189,307 $ 178,181 $ 159,844 $ 171,341

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2020
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Long-term Principal and Interest on Convertible Notes	Future minimum long‑term principal and interest on the 3.75% Convertible Notes and Credit Facilities as of June 30, 2020 are as follows (in thousands): Year Ending June 30, Long-Term Debt (1) 2021 $ 14,928 2022 39,669 2023 119,083 2024 60,530 Total $ 234,210 (1) These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company’s consolidated balance sheet. Any conversion, premium, redemption or purchase of the 3.75% Convertible Notes would impact cash payments noted in the preceding table.

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Schedule of carrying values of all Debt	The following table presents the carrying value of all Credit Facilities and 3.75% Convertible Notes (in thousands): Revolving Credit Facility (1) 3.75% Convertible Notes Term Loan Facility Total Carrying amount of equity conversion component $ — $ 14,650 $ — $ 14,650 Principal amount $ 28,001 $ 85,000 $ 89,093 $ 202,094 Unamortized debt costs — (1,922 ) (874 ) (2,796 ) Unamortized debt discount — (6,680 ) (3,311 ) (9,991 ) Net carrying amount $ 28,001 $ 76,398 $ 84,908 $ 189,307 (1) Unamortized debt costs of $0.9 million recorded in other assets on the consolidated balance sheet.
Summary of interest expense on all Credit Facilities and Convertible Notes	A summary of interest expense on the Credit Facilities and Notes is as follows (in thousands): Year ended June 30, 2020 2019 2018 Interest expense related to contractual interest coupon $ 12,373 $ 10,185 $ 9,953 Interest expense related to amortization of debt discount 4,168 3,370 3,377 Interest expense related to amortization of debt issuance costs 1,350 1,529 1,629 Total $ 17,891 $ 15,084 $ 14,959

Stock Incentive Plan and Empl_2

Stock Incentive Plan and Employee Stock Purchase Plan (Tables)	12 Months Ended
	Jun. 30, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of share-based compensation charges included in the Company's consolidated statements of operations and comprehensive income (loss)	The following table summarizes the share‑based compensation charges included in the Company’s consolidated statements of operations and comprehensive income (loss) (in thousands): Years ended June 30, 2020 2019 2018 Cost of revenue $ 1,244 $ 1,666 $ 1,866 Research and development 1,457 1,773 2,312 Selling and marketing 1,159 2,081 1,390 General and administrative 4,292 5,081 6,721 Total $ 8,152 $ 10,601 $ 12,289
Schedule of assumptions used for determining fair value of stock options	The fair value of each option is estimated at the date of grant using the Black‑Scholes option pricing formula with the following assumptions: Years Ended June 30, 2020 2019 2018 Risk–free interest rate 1.14% - 1.53% 1.94% - 2.81% 1.98 % Dividend yield — % — % — % Expected term 5.63 - 5.64 5.31 - 5.51 5.25 Expected volatility 47.3% - 48.9% 47.0% - 47.1% 43.9 %
Schedule of option activity under the Company's Incentive Plan	A summary of option activity under the Company’s incentive plan during the fiscal years is presented below (in thousands except per share and term amounts): Options Outstanding Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value Balance at June 30, 2017 2,463 $ 6.05 5.42 $ 191 Options granted 795 4.12 Options exercised (109 ) 4.02 Options forfeited/expired (465 ) 7.76 Balance at June 30, 2018 2,684 5.26 6.16 $ 60 Options granted 3,359 4.09 Options exercised (115 ) 4.26 Options forfeited/expired (708 ) 5.51 Balance at June 30, 2019 5,220 4.50 7.97 $ 11 Options granted 2,305 2.64 Options exercised — — Options forfeited/expired (1,569 ) 4.36 Balance at June 30, 2020 5,956 3.82 8.04 $ — Vested or Expected to vest at June 30, 2020 5,222 3.90 7.90 Exercisable at June 30, 2020 2,109 $ 4.73 6.47
Summary of information about outstanding and exercisable options	The following table summarizes information about outstanding and exercisable options at June 30, 2020 (in thousands, except years and exercise price): Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Number Outstanding Weighted Average Exercise Price $2.60 – 2.60 1,815 9.34 $ 2.60 — $ — $2.96 – 4.01 764 7.78 3.60 326 3.99 $4.10 – 4.10 2,543 8.42 4.10 1,007 4.10 $4.23 – 7.70 826 4.29 5.77 768 5.82 $8.01 – 8.01 2 1.00 8.01 2 8.01 $8.89 – 8.89 6 0.83 8.89 6 8.89 Total Outstanding 5,956 8.04 $ 3.82 2,109 $ 4.73
Summary of activity of RSUs, PSUs and MSUs	The following table summarizes the activity of RSUs, PSUs and MSUs (in thousands, except fair value per share): Unvested Restricted Stock Restricted Stock Units Performance Stock Units Market Stock Units Total Number of Shares Underlying Stock Awards Weighted Average Grant Date Fair Value Per Share Unvested at June 30, 2017 3,884 10 1,333 5,227 $ 5.75 Granted 1,529 53 654 2,236 4.40 Vested (1,167 ) — — (1,167 ) 6.24 Cancelled/Forfeited (546 ) — (590 ) (1,136 ) 5.87 Unvested at June 30, 2018 3,700 63 1,397 5,160 5.03 Granted 1,386 — — 1,386 3.68 Vested (1,481 ) (10 ) — (1,491 ) 5.44 Cancelled/Forfeited (521 ) (53 ) (756 ) (1,330 ) 5.10 Unvested at June 30, 2019 3,084 — 641 3,725 4.34 Granted 2,009 419 — 2,428 2.74 Vested (1,579 ) — — (1,579 ) 4.62 Cancelled/Forfeited (343 ) (470 ) (813 ) 3.96 Unvested at June 30, 2020 3,171 419 171 3,761 $ 4.34
Schedule of weighted average assumptions used for determining fair value of ESPP shares	The Company estimates the fair value of ESPP shares at the date of grant using the Black‑Scholes option pricing model. The weighted average assumptions were as follows: Years Ended June 30, 2020 2019 2018 Risk–free interest rate 0.17% - 1.60% 2.11% - 2.72% 1.07% –2.28% Dividend yield —% —% —% Expected term 0.5 - 1.0 0.5 - 1.0 0.5 – 1.0 Expected volatility 45.46% - 75.21% 30.9% - 60.0% 31.3% – 51.1%

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of components of income (loss) before provision for income taxes on the accompanying statements of operations and comprehensive loss	Income (loss) before provision for income taxes on the accompanying statements of operations and comprehensive loss included the following components (in thousands): Years Ended June 30, 2020 2019 2018 Domestic $ (1,811 ) $ (23,799 ) $ (30,747 ) Foreign 7,501 9,455 7,726 Total worldwide $ 5,690 $ (14,344 ) $ (23,021 )
Schedule of provision for income taxes	The provision for income taxes consisted of the following (in thousands): Years Ended June 30, 2020 2019 2018 Current: Federal $ — $ — $ — State 15 32 63 Foreign 1,495 2,140 785 Total current $ 1,510 $ 2,172 $ 848 Deferred: Federal — — — State — — — Foreign 353 (86 ) 30 Total deferred 353 (86 ) 30 Total provision for income taxes $ 1,863 $ 2,086 $ 878
Schedule of reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss	Income tax payable was $0.8 million, $1.6 million and $1.1 million at June 30, 2020, 2019 and 2018, respectively. A reconciliation of income taxes at the statutory federal income tax rate to the provision for income taxes included in the accompanying consolidated statements of operations and comprehensive loss is as follows (in thousands): Years Ended June 30, 2020 2019 2018 U.S. federal taxes (benefit): At federal statutory rate $ 1,195 $ (3,012 ) $ (6,446 ) State tax, net of federal benefit 15 32 63 Share-based compensation expense 810 1,128 1,712 Debt extinguishment — — 967 Other non-deductible permanent items 418 486 702 R&D credits (635 ) (877 ) (142 ) Foreign taxes 273 (38 ) (1,295 ) Other (69 ) 58 (228 ) Transition Tax — — 3,348 Tax Cuts and Jobs Act — — 54,072 Global Intangible Low-Taxed Income 1,185 1,924 — Change in valuation allowance (1,329 ) 2,385 (51,875 ) Total $ 1,863 $ 2,086 $ 878
Schedule of significant components of net deferred tax assets	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets were as follows (in thousands): June 30, 2020 2019 Deferred tax assets: Federal and state net operating losses $ 75,615 $ 77,228 Accrued expenses and reserves 4,972 7,497 Lease liability 5,366 — Deferred revenue 5,038 2,897 R&D Credits 22,843 22,108 Share-based compensation expense 1,337 1,327 Capitalized research and development 2,683 3,343 Unicap 2,105 1,953 Fixed assets/intangibles 1,199 1,323 Section 163(j) interest 1,823 1,857 Other 1,290 1,582 Total deferred tax assets 124,271 121,115 Deferred tax liabilities: Contract acquisition costs (977 ) (1,146 ) Right of use assets (4,508 ) — Total deferred tax liabilities (5,485 ) (1,146 ) Valuation allowance (118,300 ) (119,125 ) Net deferred tax assets $ 486 $ 844
Schedule of aggregate changes in the balance of gross unrecognized tax benefits	The aggregate changes in the balance of gross unrecognized tax benefits were as follows (in thousands): Years Ended June 30, 2020 2019 2018 Balance at beginning of year $ 16,280 $ 15,299 $ 15,819 Tax positions related to current year: Additions 954 934 823 Tax positions related to prior years: Additions 286 580 — Reductions (524 ) (533 ) (1,343 ) Balance at end of year $ 16,996 $ 16,280 $ 15,299

Defined Benefit Pension Oblig_2

Defined Benefit Pension Obligation (Tables)	12 Months Ended
	Jun. 30, 2020
Defined Benefit Pension Obligation Disclosure [Abstract]
Schedule of funded status	The following table presents the funded status of the defined benefit pension plan (in thousands): June 30, 2020 2019 Change in benefit obligation: Benefit obligation—beginning of fiscal year $ 17,577 $ 14,254 Service cost 2,003 1,865 Interest cost 62 128 Plan participants’ contributions 2,886 1,818 Plan amendment 975 — Actuarial (gain)/loss (615 ) 742 Foreign currency changes 545 250 Benefit and expense payments (5,007 ) (1,480 ) Benefit obligation—end of fiscal year $ 18,426 $ 17,577 Change in plan assets: Plan assets—beginning of fiscal year $ 14,228 $ 12,192 Employer contributions 1,327 1,373 Actual return on plan assets 112 122 Plan participants’ contributions 2,885 1,818 Foreign currency changes 413 203 Benefit and expense payments (5,007 ) (1,480 ) Plan assets—end of fiscal year $ 13,958 $ 14,228 Funded status $ (4,468 ) $ (3,349 ) Amounts recognized within the consolidated balance sheets: Assets $ — $ — Long-term other liabilities (4,468 ) (3,349 ) Net amount recognized $ (4,468 ) $ (3,349 )
Schedule of amounts recognized in accumulated other comprehensive loss (before tax)	The following table presents the amounts recognized in accumulated other comprehensive loss (before tax) for the defined benefit pension plan (in thousands): June 30, 2020 2019 Net loss $ (1,000 ) $ (144 ) Total recognized in other comprehensive income (loss) (236 ) (856 ) Accumulated other comprehensive loss $ (1,236 ) $ (1,000 )
Schedule of projected benefit obligations, accumulated benefit obligation and fair value of plan assets where accumulated benefit obligation exceeded fair value of plan assets	The following table presents the projected benefit obligation, accumulated benefit obligation and fair value of plan assets for this defined benefit pension plan where accumulated benefit obligation exceeded the fair value of plan assets (in thousands): June 30, 2020 2019 Projected benefit obligation $ 18,426 $ 17,577 Accumulated benefit obligation $ 16,175 $ 15,506 Fair value of plan assets $ 13,958 $ 14,228
Schedule Of Net Benefit Costs And Other Amounts Recognized In Other Comprehensive Income Loss Table Text Block	The following table shows the components of the Company’s net periodic benefit costs and the other amounts recognized in other comprehensive loss, before tax, related to the Company’s defined benefit pension plan (in thousands): Year ended June 30, 2020 2019 2018 Net Periodic Benefit Costs: Service cost $ 2,003 $ 1,865 $ 1,887 Interest cost 62 128 97 Expected returns on assets (151 ) (170 ) (156 ) Amortization of prior service cost (2 ) (55 ) (44 ) Amortization of net loss — — 11 Settlement charges 178 — — Net periodic benefit costs 2,090 1,768 1,795 Other Amounts Recognized in Other Comprehensive Loss: Net (gain) loss arising during the year (593 ) 801 (901 ) Prior service cost 2 — (105 ) Amortization of prior service cost 1,005 55 44 Amortization of net gain — — (11 ) Effect of settlement (178 ) Total recognized in other comprehensive (gain) loss 236 856 (973 ) Total recognized in net periodic benefit costs and other comprehensive loss $ 2,326 $ 2,624 $ 822
Schedule of amounts in accumulated other comprehensive loss that are expected to be recognized	The amounts in accumulated other comprehensive loss that are expected to be recognized as components of net periodic benefit cost during fiscal year 2021 related to the Company’s defined benefit pension plan are as follows (in thousands): 2021 Net loss $ 852 Prior service credit 506 Accumulated other comprehensive loss $ 1,358
Schedule of assumptions used to determine net periodic benefit cost and benefit obligation	The assumptions used to determine net periodic benefit cost and to compute the expected long‑term return on assets for the Company’s defined benefit pension plan were as follows: Fiscal Years 2020 2019 2018 Net Periodic Benefit Costs: Discount rate 0.25 % 0.45 % 0.90 % Rate of compensation increase 1.50 % 1.50 % 1.50 % Expected long-term return on assets 1.00 % 1.20 % 1.40 % The assumptions used to measure the benefit obligation for the Company’s defined benefit pension plan were as follows: June 30, 2020 2019 Benefit Obligation: Discount rate 0.25 % 0.45 % Rate of compensation increase 1.50 % 1.50 %
Schedule of estimated future benefit payments	Estimated future benefit payments expected to be paid by the defined benefit pension plan at June 30, 2020 are as follows (in thousands): Year Ending June 30, Future Benefits 2021 $ 2,344 2022 816 2023 746 2024 688 2025 763 Thereafter 3,189 Total $ 8,546

Segment Disclosure (Tables)

Segment Disclosure (Tables)	12 Months Ended
	Jun. 30, 2020
Segment Reporting [Abstract]
Summary of Revenue by Geographic Region	Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands): Years ended June 30, 2020 2019 2018 Americas $ 128,562 $ 135,683 $ 145,689 Europe, Middle East, India and Africa 119,989 149,095 120,032 Asia Pacific (excluding Japan and India) 61,689 63,793 72,925 Japan 72,688 70,214 66,251 Total $ 382,928 $ 418,785 $ 404,897
Schedule of Geographic Areas in Which the Company has Long Lived Tangible Assets	Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands): June 30, 2020 June 30, 2019 Americas $ 12,807 $ 13,853 Europe, Middle East, India and Africa 373 575 Asia Pacific (excluding Japan and India) 986 1,419 Japan 1,183 1,275 Total $ 15,349 $ 17,122

Quarterly Financial Data (una_2

Quarterly Financial Data (unaudited) (Tables)	12 Months Ended
	Jun. 30, 2020
Quarterly Financial Data [Abstract]
Schedule of selected quarterly financial data (unaudited)	The following table provides the selected quarterly financial data for fiscal 2020 and 2019 (in thousands, except net income (loss) per share amounts: Quarters ended September 30, 2019 December 31, 2019 March 31, 2020 June 30, 2020 Net revenue $ 89,577 $ 98,826 $ 99,548 $ 94,977 Gross profit $ 32,943 $ 37,900 $ 39,133 $ 39,745 Net Income (loss) $ (9,356 ) $ 10,710 $ 2,625 $ (152 ) Net income (loss) per share - basic $ (0.11 ) $ 0.12 $ 0.03 $ (0.00 ) Net income (loss) per share - diluted $ (0.11 ) $ 0.12 $ 0.03 $ (0.00 ) Weighted average common shares used in computing net income (loss) per share: Basic 88,772 89,517 90,476 90,748 Diluted 88,772 90,279 90,855 90,748 Quarters ended September 30, 2018 December 31, 2018 March 31, 2019 June 30, 2019 Net revenue $ 95,829 $ 102,318 $ 103,221 $ 117,417 Gross profit $ 37,879 $ 38,380 $ 40,466 $ 45,926 Net income loss $ (9,206 ) $ (4,640 ) $ (1,184 ) $ (1,400 ) Net loss per share—basic and diluted $ (0.11 ) $ (0.05 ) $ (0.01 ) $ (0.02 ) Shares used in basic and diluted per share calculation 86,479 87,237 87,962 88,202

The Company and its Significa_4

The Company and its Significant Accounting Policies - Additional Information (Details) shares in Millions	12 Months Ended
	Jun. 30, 2020USD ($)Customersegmentshares	Jun. 30, 2019USD ($)Customer	Jun. 30, 2018USD ($)Customer	Aug. 31, 2017
Concentration Risk [Line Items]
Issuance of invoices for unbilled receivables period	12 months
Capitalized development of software costs	$ 0
Number of operating segments | segment	1
Number of reporting units | segment	1
Impairment of goodwill	$ 0	$ 0	$ 0
Advertising expenses	200,000	$ 500,000	$ 400,000
Reduction in uncertain tax position due to lapse of various statutes of limitation	$ 10,000
Subsequent period within which no material changes in unrecognized tax benefits are expected	12 months
Stock options
Concentration Risk [Line Items]
Expiration period	10 years
Machinery and equipment
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	5 years
Furniture and fixtures
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	4 years
Computer and office equipment
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	3 years
Computer Software
Concentration Risk [Line Items]
Period over which property and equipment are depreciated	3 years
Maximum
Concentration Risk [Line Items]
Estimated useful lives of purchased intangible assets	7 years
Minimum
Concentration Risk [Line Items]
Estimated useful lives of purchased intangible assets	1 year
Total net revenue | Customer concentration risk
Concentration Risk [Line Items]
Percentage of concentration risk	10.00%	10.00%	10.00%
Total net revenue | Customer concentration risk | Minimum
Concentration Risk [Line Items]
Number of significant customers | Customer	0	0	0
Total accounts receivable | Credit concentration risk
Concentration Risk [Line Items]
Number of significant customers | Customer	1	1
Total accounts receivable | Credit concentration risk | Minimum
Concentration Risk [Line Items]
Percentage of concentration risk	10.00%	10.00%
3.75% Convertible Senior Notes due 2022
Concentration Risk [Line Items]
Interest rate (as a percent)	3.75%	3.75%		3.75%
Common stock not included in the calculation of potentially diluted shares | shares	14.9
3.75% Convertible Notes
Concentration Risk [Line Items]
Interest rate (as a percent)	3.75%
Convertible debt maturity period	2022-08
3.50% Convertible Senior Notes
Concentration Risk [Line Items]
Interest rate (as a percent)	3.50%
Convertible debt maturity maturity date	Feb. 1, 2018
3.50% Series A Convertible Notes
Concentration Risk [Line Items]
Interest rate (as a percent)	3.50%
Convertible debt maturity maturity date	Feb. 1, 2018

The Company and its Significa_5

The Company and its Significant Accounting Policies - Schedule of reconciliation of the numerator and denominator used in the calculation of basic and diluted net income (loss) per common share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Numerator:
Net income (loss) used to compute basic and diluted loss per share	$ (152)	$ 2,625	$ 10,710	$ (9,356)	$ (1,400)	$ (1,184)	$ (4,640)	$ (9,206)	$ 3,827	$ (16,430)	$ (23,899)
Weighted average common shares used in computing net income (loss) per share:
Weighted average shares used to compute basic income (loss) per share	90,748	90,476	89,517	88,772					89,874	87,465	84,893
Weighted average shares used to compute diluted income (loss) per share	90,748	90,855	90,279	88,772					90,623	87,465	84,893

The Company and its Significa_6

The Company and its Significant Accounting Policies - Schedule of all potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per common share (Details) - shares shares in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income (loss) per share (in shares)	9,717	8,945	7,843
Stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income (loss) per share (in shares)	5,956	5,220	2,684
RSUs, PSUs and MSUs
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net income (loss) per share (in shares)	3,761	3,725	5,159

Recent Accounting Pronounceme_3

Recent Accounting Pronouncements - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jul. 01, 2019	Jun. 30, 2019
Operating lease right of use assets	$ 28,647		$ 30,578
Operating lease liabilities	$ 32,397		$ 34,465
ASU 2016-02
Operating lease right of use assets		$ 30,600
Operating lease liabilities		$ 34,500

Revenue -Summary of Contract wi

Revenue -Summary of Contract with Customer, Asset and Liability (Details) - USD ($) $ in Thousands		Jun. 30, 2020	Jun. 30, 2019
ASSETS
Unbilled accounts receivable – current	[1]	$ 11,739	$ 5,260
Interest receivable – current	[2]	493	361
Long-term accounts receivable	[3]	3,810	4,116
Interest receivable – non-current	[3]	1,342	1,255
Liabilities:
Customer advances		22,571	20,395
Deferred revenue – current		83,207	78,332
Deferred revenue – non-current		$ 24,125	$ 26,639
[1]	Included in accounts receivable on consolidated balance sheets
[2]	Included in prepaid expenses and other current assets on consolidated balance sheets
[3]	Included in other assets on consolidated balance sheets

Revenue - Additional Informatio

Revenue - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Recognition of deferred revenue	$ 87.7	$ 78.6
Remaining performance obligations amount	$ 976.3
Percentage of changes in operating results on entity's revenue	21.00%
Capitalized contract cost, amortization period	5 years
Capitalized costs to obtain a contract	$ 7.9	8.4
Impairment loss	1.2	0.5
Capitalized contract cost, amortization	1.9	$ 2.2
Long-term Warranty and Service
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	78.5
Performance Obligations Other Than Warrant
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations amount	$ 897.8

Revenue - Schedule of Remaining

Revenue - Schedule of Remaining Performance Obligations related to Warranty (Details) - Long-term Warranty and Service $ in Thousands	Jun. 30, 2020USD ($)
2021	$ 35,223
2022	23,957
2023	9,833
Thereafter	$ 9,470

Revenue - Additional Informat_2

Revenue - Additional Information (Details1) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2020-07-01	Jun. 30, 2020
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations recognized period	12 months
Minimum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	21.00%
Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining performance obligations percentage	28.00%

Supplemental Financial Inform_3

Supplemental Financial Information - Schedule of Accounts Receivable, Net (Details) - USD ($) $ in Thousands		Jun. 30, 2020	Jun. 30, 2019
Accounts receivable, net
Accounts receivable		$ 80,128	$ 107,230
Unbilled fees and services	[1]	11,739	5,260
Accounts and other receivable, gross		91,867	112,490
Less: Allowance for doubtful accounts		(1,268)	(605)
Accounts receivable, net	[2]	$ 90,599	$ 111,885
[1]	Included in accounts receivable on consolidated balance sheets
[2]	Include accounts receivable from the China joint venture of $3,039 and $0 at June 30, 2020 and June 30, 2019, respectively. See Note 13

Supplemental Financial Inform_4

Supplemental Financial Information - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Accounts receivable, net
Allowance for doubtful accounts, payments and credits	$ 400	$ 200
Allowance for doubtful accounts, additions	1,200	600
Allowance for doubtful accounts, write-offs	100
Financing receivables
Accounts receivable with contractual maturities of more than one year	3,792	4,269
Adjustments to allowance for credit loss	800	3,600
Property and equipment, net
Depreciation expense	$ 7,300	$ 8,100	$ 9,600

Supplemental Financial Inform_5

Supplemental Financial Information - Summary of Financing Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Financing receivables
Gross	$ 13,019	$ 13,288
Unearned income	(1,774)	(1,535)
Allowance for credit loss	(4,369)	(3,582)
Total, net	6,876	8,171
Current	3,084	3,902
Non-current	$ 3,792	$ 4,269

Supplemental Financial Inform_6

Supplemental Financial Information - Summary of Inventories, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Inventory Net [Abstract]
Raw materials	$ 48,037	$ 40,966
Work-in-process	17,798	18,152
Finished goods	68,539	61,705
Inventories, net	$ 134,374	$ 120,823

Supplemental Financial Inform_7

Supplemental Financial Information - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Property and equipment, net
Property and equipment, gross	$ 100,122	$ 98,018
Less: Accumulated depreciation	(84,773)	(80,896)
Property and equipment, net	15,349	17,122
Furniture and Fixtures
Property and equipment, net
Property and equipment, gross	1,961	2,728
Computer and Office Equipment
Property and equipment, net
Property and equipment, gross	10,896	11,183
Software
Property and equipment, net
Property and equipment, gross	11,606	11,236
Leasehold Improvements
Property and equipment, net
Property and equipment, gross	26,206	25,741
Machinery and Equipment
Property and equipment, net
Property and equipment, gross	48,830	45,472
Construction in Progress
Property and equipment, net
Property and equipment, gross	$ 623	$ 1,658

Supplemental Financial Inform_8

Supplemental Financial Information - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Accumulated Other Comprehensive Income (Loss)
Balance	$ 49,871	$ 48,632
Balance	63,635	49,871
Foreign Currency Items
Accumulated Other Comprehensive Income (Loss)
Balance	990	1,237
Other comprehensive loss	(238)	(247)
Balance	752	990
Change in Defined Pension Benefit Obligation
Accumulated Other Comprehensive Income (Loss)
Balance	(1,000)	(144)
Other comprehensive loss	(236)	(856)
Balance	(1,236)	(1,000)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss)
Balance	(10)	1,093
Other comprehensive loss	(474)	(1,103)
Balance	$ (484)	$ (10)

Supplemental Financial Inform_9

Supplemental Financial Information - Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Supplemental Financial Information Disclosure [Abstract]
Interest expense	$ (18,080)	$ (15,084)	$ (14,959)
Foreign currency transaction loss	(2,343)	(665)	(986)
Gain on contribution to equity method investment	12,964
Other (expense) income	759	822	(3,279)
Total other expense, net	$ (6,700)	$ (14,927)	$ (19,224)

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	12 Months Ended
	Jun. 30, 2020USD ($)
Leases [Abstract]
Operating lease costs	$ 9.5
Cash paid for amounts included in the measurement of operating lease liabilities	9.5
Operating lease liabilities arising from obtaining operating right of-use assets	$ 5.2

Leases - Schedule of Operating

Leases - Schedule of Operating Lease Right-of-use Assets and Operating Lease Obligation (Details) $ in Thousands	12 Months Ended
	Jun. 30, 2020USD ($)
Leases [Abstract]
Operating lease right-of-use asset, beginning balance	$ 30,578
Operating lease, lease asset added after initial recognition	5,244
Operating lease, amortization for the year	(7,175)
Operating lease right-of-use asset, ending balance	28,647
Operating lease obligation, beginning balance	34,465
Operating lease, lease liability added after initial recognition	5,244
Operating lease repayment and interest accretion	(7,312)
Operating lease obligation, ending balance	32,397
Operating lease liabilities, current	8,224
Operating lease liabilities, non-current	24,173
Finance lease, lease asset added after initial recognition	10
Finance lease, amortization for the year	(2)
Finance lease right-of-use asset, ending balance	8
Finance lease, lease liability added after initial recognition	10
Finance lease repayment and interest accretion	(2)
Finance lease obligation, ending balance	8
Current portion of finance lease obligation	5
Noncurrent portion of finance lease obligation	3
Lease right-of-use asset, beginning balance	30,578
Lease asset added after initial recognition	5,254
Lease, amortization for the year	(7,177)
Lease right-of-use asset, ending balance	28,655
Lease obligation, beginning balance	34,465
Lease liability added after initial recognition	5,254
Lease repayment and interest accretion	(7,314)
Lease obligation, ending balance	32,405
Current portion of lease obligation	8,229
Noncurrent portion of lease obligation	$ 24,176

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Details) $ in Thousands	Jun. 30, 2020USD ($)
Leases [Abstract]
2021	$ 9,449
2022	9,130
2023	8,510
2024	5,812
2025	3,005
Total operating lease payments	35,906
Less: imputed interest	(3,501)
Present value of operating lease liabilities	$ 32,405
Weighted average remaining lease term (in years)	3 years 11 months 8 days
Weighted average discount rate	5.30%

Goodwill and Purchased Intang_3

Goodwill and Purchased Intangible Assets - Schedule of Goodwill and Changes in the Carrying Amount of Goodwill (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Changes in the carrying amount of goodwill
Balance at the beginning of the period	$ 57,770	$ 57,855
Currency translation	(53)	(85)
Balance at the end of the period	$ 57,717	$ 57,770

Goodwill and Purchased Intang_4

Goodwill and Purchased Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Finite Lived Intangible Assets [Line Items]
Impairment of goodwill			$ 0	$ 0	$ 0
Purchase of intangible assets			170,000		333,000
Amortization expense			$ 200,000	$ 100,000	$ 100,000
Patent license
Finite Lived Intangible Assets [Line Items]
Useful Lives		2 years				7 years
Purchase of intangible assets		$ 170,000
COVID-19 Pandemic
Finite Lived Intangible Assets [Line Items]
Impairment of goodwill	$ 0	$ 0

Goodwill and Purchased Intang_5

Goodwill and Purchased Intangible Assets - Schedule of Intangible Assets Associated with Purchased Patent License (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Jun. 30, 2017	Jun. 30, 2019
Finite Lived Intangible Assets [Line Items]
Net Amount		$ 663		$ 679
Minimum
Finite Lived Intangible Assets [Line Items]
Useful Lives		1 year
Maximum
Finite Lived Intangible Assets [Line Items]
Useful Lives		7 years
Patent license
Finite Lived Intangible Assets [Line Items]
Useful Lives	2 years		7 years
Gross Carrying Amount		$ 1,170		1,000
Accumulated Amortization		(507)		(321)
Net Amount		$ 663		$ 679
Patent license | Minimum
Finite Lived Intangible Assets [Line Items]
Useful Lives		2 years
Patent license | Maximum
Finite Lived Intangible Assets [Line Items]
Useful Lives		7 years

Goodwill and Purchased Intang_6

Goodwill and Purchased Intangible Assets - Schedule of Estimated Future Amortization Expense of Purchased Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Estimated future amortization expense of purchased intangible assets
2021	$ 228
2022	185
2023	143
2024	107
Net Amount	$ 663	$ 679

Derivative Financial Instrume_3

Derivative Financial Instruments - Additional Information (Details) - contract	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Outstanding foreign currency contracts (number of contracts)		0	0
Maximum
Length of forward contracts	three months

Derivative Financial Instrume_4

Derivative Financial Instruments - Schedule of Effect of Forward Contracts Not Designated as Hedging Instruments and Foreign Currency Transactions Gains and Losses (Details) - Other expense, net - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Foreign currency exchange gain (loss) on foreign contracts	$ (3,087)	$ (682)	$ 1,475
Foreign contracts
Foreign currency exchange gain (loss) on foreign contracts	$ 744	$ 17	$ (2,461)

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019	Aug. 31, 2017
Financial assets
Cash and cash equivalents	$ 107,577	$ 76,798
3.75% Convertible Notes
Financial assets
Interest rate (as a percent)	3.75%	3.75%	3.75%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Carrying Value and Estimated Fair Value of all Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Carrying Value
Fair value measurement
Long term debt	$ 189,307	$ 159,844
Fair Value
Fair value measurement
Long term debt	178,181	171,341
Non-recurring basis | Carrying Value | Level 2 | 3.75% Convertible Notes
Fair value measurement
Long term debt	76,398	72,730
Non-recurring basis | Fair Value | Level 2 | 3.75% Convertible Notes
Fair value measurement
Long term debt	65,272	84,227
Term loan | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	84,908	58,849
Term loan | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	84,908	58,849
Revolving Credit Facility | Non-recurring basis | Carrying Value | Level 2
Fair value measurement
Long term debt	28,001	28,265
Revolving Credit Facility | Non-recurring basis | Fair Value | Level 2
Fair value measurement
Long term debt	$ 28,001	$ 28,265

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	12 Months Ended
	Jun. 30, 2020USD ($)Guarantee	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)
License agreement | WARF (Wisconsin Alumni Research Foundation)
Loss Contingencies [Line Items]
License agreement expiration date	Aug. 6, 2019
Royalty costs	$ 50,000	$ 600,000	$ 500,000
Royalty amount accrued	$ 0	200,000
Financial Guarantee | Three Customers
Loss Contingencies [Line Items]
Number of bank guarantees | Guarantee	3
Bank guarantees	$ 1,000,000
Financial Guarantee | Two Customers
Loss Contingencies [Line Items]
Bank guarantees		$ 700,000
3.75% Convertible Notes
Loss Contingencies [Line Items]
Interest rate (as a percent)	3.75%

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Long-term Principal and Interest on Convertible Notes (Details) $ in Thousands	Jun. 30, 2020USD ($)	[1]
Long-term principal and interest on Convertible Notes
2021	$ 14,928
2022	39,669
2023	119,083
2024	60,530
Total	$ 234,210
[1]	These amounts represent principal and interest cash payments over the contractual life of the debt obligations, including anticipated interest payments that are not recorded on the Company’s consolidated balance sheet. Any conversion, premium, redemption or purchase of the 3.75% Convertible Notes would impact cash payments noted in the preceding table.

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Future Minimum Long-term Principal and Interest on Convertible Notes (Details) (Parenthetical) (Details)	Jun. 30, 2020	Jun. 30, 2019	Aug. 31, 2017
3.75% Convertible Senior Notes due 2022
Debt
Interest rate (as a percent)	3.75%	3.75%	3.75%

Debt - Additional Information (

Debt - Additional Information (Details)

Jun. 14, 2017USD ($)

Aug. 31, 2019USD ($)

Jul. 31, 2019

May 31, 2019USD ($)

Apr. 30, 2019

Dec. 31, 2018USD ($)

Dec. 31, 2017USD ($)

Jun. 30, 2020USD ($)$ / shares

Jun. 30, 2019

Aug. 31, 2017USD ($)

Apr. 30, 2014

Feb. 28, 2013

Debt

Principal amount of the Notes

$ 202,094,000

Unamortized debt costs

2,796,000

Debt discount costs

9,991,000

Revolving Credit Facility

Debt

Principal amount of the Notes

[1]

28,001,000

Initial borrowing capacity

$ 52,000,000

Minimum drawn balance (as a percent)

30.00%

Outstanding revolving credit facility

28,000,000

Revolving Credit Facility | Other Assets

Debt

Unamortized debt costs

$ 900,000

90-day LIBOR | Revolving Credit Facility

Debt

Interest rate determination basis

90-day LIBOR

Variable rate (as a percent)

4.50%

3.50%

4.50%

3.75% Convertible Senior Notes due 2022

Debt

Aggregate principal amount of debt issued

$ 85,000,000

Interest rate (as a percent)

3.75%

3.75%

3.75%

Conversion rate, number of shares to be issued per $1000 of principal amount (in shares)

174.8252

Principal amount used for debt instrument conversion ratio

$ 1,000

Conversion price (in dollars per share) | $ / shares

$ 5.72

Repurchase price, as a percentage of the principal amount, in the event of a fundamental change, as defined in Indenture

100.00%

Principal amount of the Notes

$ 85,000,000

Unamortized debt costs

1,922,000

Debt discount costs

6,680,000

3.50% Convertible Notes

Debt

Interest rate (as a percent)

3.50%

3.50% Series A Convertible Senior Notes

Debt

Interest rate (as a percent)

3.50%

Exchange | 3.75% Convertible Senior Notes due 2022

Debt

Aggregate principal amount of debt issued

$ 53,000,000

Exchange | 3.50% Convertible Notes due 2018 and 3.5% Series A Senior Notes due February 2018

Debt

Aggregate principal amount of debt issued

47,000,000

Repurchase

Debt

Repurchase/Retirement of existing notes

28,000,000

Repurchase | 3.75% Convertible Senior Notes due 2022

Debt

Aggregate principal amount of debt issued

$ 32,000,000

Revolving Credit Agreement | Revolving Credit Facility

Debt

Reduced borrowing capacity

$ 32,000,000

Term Loan Facility due December 2022

Debt

Principal amount of the Notes

89,093,000

Unamortized debt costs

874,000

Debt discount costs

$ 3,311,000

Term Loan Facility due December 2022 | Term loan

Debt

Initial term loan borrowing capacity

40,000,000

Additional term loan borrowing capacity

$ 20,000,000

Loan prepayment fees for first year (percentage)

3.00%

Loan prepayment fees for second year (percentage)

2.00%

Loan prepayment fees for third year (percentage)

1.00%

Term of loan (in months)

60 months

Term of interest payable (in months)

24 months

Administrative fee payable on term loan as a percentage

0.25%

Final payment of administrative fee payable on term loan as a percentage

4.00%

Debt instrument amount withdrawn

$ 5,000,000

Debt instrument scheduled commitment extended termination date

Jun. 30, 2019

Debt instrument remaining unfunded commitment amount

$ 15,000,000

Term Loan Facility due December 2022 | 90-day LIBOR | Term loan

Debt

Interest rate determination basis

90-day LIBOR

Variable rate (as a percent)

6.75%

Term Loan Facility Due May 2024 | Term loan

Debt

Principal amount of the Notes

$ 89,100,000

Debt instrument increased commitment amount

$ 25,000,000

$ 500,000

Debt discount costs

$ 1,600,000

$ 1,500,000

Term Loan Facility Due May 2024 | 90-day LIBOR | Term loan

Debt

Interest rate determination basis

90-day LIBOR

Variable rate (as a percent)

6.75%

5.50%

5.50%

6.75%

[1]

Unamortized debt costs of $0.9 million recorded in other assets on the consolidated balance sheet.

Debt - Schedule of Carrying Val

Debt - Schedule of Carrying Values of All Debt (Details) $ in Thousands	Jun. 30, 2020USD ($)
Debt
Carrying amount of equity conversion component	$ 14,650
Principal amount	202,094
Unamortized debt costs	(2,796)
Unamortized debt discount	(9,991)
Net carrying amount	189,307
Revolving Credit Facility
Debt
Principal amount	28,001	[1]
Net carrying amount	28,001	[1]
3.75% Convertible Senior Notes due 2022
Debt
Carrying amount of equity conversion component	14,650
Principal amount	85,000
Unamortized debt costs	(1,922)
Unamortized debt discount	(6,680)
Net carrying amount	76,398
Term Loan Facility due December 2022
Debt
Principal amount	89,093
Unamortized debt costs	(874)
Unamortized debt discount	(3,311)
Net carrying amount	$ 84,908
[1]	Unamortized debt costs of $0.9 million recorded in other assets on the consolidated balance sheet.

Debt - Schedule of Carrying V_2

Debt - Schedule of Carrying Values of All Debt (Parenthetical) (Details) $ in Thousands	Jun. 30, 2020USD ($)
Debt
Unamortized debt costs	$ 2,796
Revolving Credit Facility | Other Assets
Debt
Unamortized debt costs	$ 900

Debt - Summary of interest expe

Debt - Summary of interest expense on all Credit Facilities and Convertible Notes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Debt Disclosure [Abstract]
Interest expense related to contractual interest coupon	$ 12,373	$ 10,185	$ 9,953
Interest expense related to amortization of debt discount	4,168	3,370	3,377
Interest expense related to amortization of debt issuance costs	1,350	1,529	1,629
Total	$ 17,891	$ 15,084	$ 14,959

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) shares in Millions	Jun. 30, 2020shares
Stockholders Equity Note [Abstract]
Number of shares of common stock reserved for issuance under stock incentive plans and employee stock purchase plan	9.7

Stock Incentive Plan and Empl_3

Stock Incentive Plan and Employee Stock Purchase Plan - Additional Information (Details)	12 Months Ended
	Jun. 30, 2020USD ($)PlanItem$ / sharesshares	Jun. 30, 2019USD ($)$ / sharesshares	Dec. 31, 2018$ / sharesshares	Jun. 30, 2018USD ($)$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock incentive plans | Plan	3
Fair value of common stock (in dollars per share) | $ / shares	$ 2.03
Share-based compensation expense	$ 8,152,000	$ 10,601,000		$ 12,289,000
ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 1,100,000	$ 1,100,000		1,200,000
Weighted average period for recognition of compensation costs	6 months
Unrecognized compensation cost	$ 600,000
Purchase price expressed as percentage of fair market value of common stock	85.00%
Shares issued under the ESPP | shares	1,100,000	900,000	900,000
Weighted average fair value (in dollars per share) | $ / shares	$ 2.16	$ 3.31	$ 3.62
Maximum | ESPP
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Payroll deductions as percentage of salaries	10.00%
Number of shares per period up to which employees may purchase | shares	2,500
Value of shares up to which employees may purchase in any calendar year	$ 25,000
Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of options exercised	0	$ 100,000		100,000
Share-based compensation expense	2,000,000	1,400,000		600,000
Realized excess tax benefits related to stock options exercises	0	0		0
Unrecognized compensation cost related to unvested stock options, net of estimated forfeitures	$ 6,700,000
Weighted average period for recognition of compensation costs	2 years 10 months 20 days
Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 4,900,000	$ 7,200,000		$ 7,800,000
Weighted average period for recognition of compensation costs	1 year 9 months 3 days
Unrecognized compensation cost	$ 8,700,000
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 2.74	$ 3.68		$ 4.57
Aggregate fair market value of units vested	$ 4,700,000
Granted (in shares) | shares	2,009,000	1,386,000		1,529,000
Vested (in shares) | shares	1,579,000	1,481,000		1,167,000
Cancelled/Forfeited (in shares) | shares	343,000	521,000		546,000
Performance Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Granted (in shares) | shares	419,000	0		53,000
Vested (in shares) | shares	0	10,000		0
Cancelled (in shares) | shares	0	53,000		0
Share-based compensation expense (benefit)	$ 0	$ (100,000)		$ 100,000
Cancelled/Forfeited (in shares) | shares		53,000
Market Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	200,000	$ 1,000,000		$ 2,600,000
Unrecognized compensation cost	$ 100,000
Weighted average grant date fair value (in dollars per share) | $ / shares				$ 4.11
Granted (in shares) | shares	0	0		654,000
Vested (in shares) | shares	0	0		0
Cancelled/Forfeited (in shares) | shares	470,000	756,000		590,000
2007 Amended and Restated Plan | Stock options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Contractual term	10 years
Percentage of the award vesting at first anniversary	25.00%
Vesting period for first 25% vesting rights	1 year
Remainder vesting period	36 months
2007 Amended and Restated Plan | Stock options | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price of stock options as a percentage of fair market value on the grant date	100.00%
2007 Amended and Restated Plan | Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of the award vesting at first anniversary	50.00%
Percentage of the award vesting at second anniversary	50.00%
2007 Amended and Restated Plan | Time-based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Annual vesting percentage	25.00%
MSU Program | Market Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation expense	$ 0	$ 0		$ 600,000
Number of measurement periods | Item	2
MSU Program | Market Stock Units | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Target number of shares that participating executives may earn (as a percent)	150.00%

Stock Incentive Plan and Empl_4

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Share-based Compensation Charges Included in the Company's Consolidated Statements of Operations and Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Share-based compensation expenses
Share-based compensation expense	$ 8,152	$ 10,601	$ 12,289
Cost of revenue
Share-based compensation expenses
Share-based compensation expense	1,244	1,666	1,866
Research and development
Share-based compensation expenses
Share-based compensation expense	1,457	1,773	2,312
Selling and marketing
Share-based compensation expenses
Share-based compensation expense	1,159	2,081	1,390
General and administrative
Share-based compensation expenses
Share-based compensation expense	$ 4,292	$ 5,081	$ 6,721

Stock Incentive Plan and Empl_5

Stock Incentive Plan and Employee Stock Purchase Plan - Schedule of Assumptions Used for Determining Fair Value of Stock Options (Details) - Stock options	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Weighted average assumptions used for determining fair value of options
Risk-free interest rate (as a percent)			1.98%
Risk-free interest rate, Minimum (as a percent)	1.14%	1.94%
Risk-free interest rate, Maximum (as a percent)	1.53%	2.81%
Expected term (in years)			5 years 3 months
Expected volatility (as a percent)			43.90%
Expected volatility, Minimum (as a percent)	47.30%	47.00%
Expected volatility, Maximum (as a percent)	48.90%	47.10%
Minimum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	5 years 7 months 17 days	5 years 3 months 21 days
Maximum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	5 years 7 months 20 days	5 years 6 months 3 days

Stock Incentive Plan and Empl_6

Stock Incentive Plan and Employee Stock Purchase Plan - Schedule of Option Activity Under the Company's Incentive Plan (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Options Outstanding
Balance at the beginning of the year (in shares)	5,220	2,684	2,463
Options granted (in shares)	2,305	3,359	795
Options exercised (in shares)		(115)	(109)
Options forfeited/expired (in shares)	(1,569)	(708)	(465)
Balance at the end of the year (in shares)	5,956	5,220	2,684	2,463
Vested or Expected to vest at the end of the year (in shares)	5,222
Exercisable at the end of the year (in shares)	2,109
Weighted Average Exercise Price
Balance at the beginning of the year (in dollars per share)	$ 4.50	$ 5.26	$ 6.05
Options granted (in dollars per share)	2.64	4.09	4.12
Options exercised (in dollars per share)		4.26	4.02
Options forfeited/expired (in dollars per share)	4.36	5.51	7.76
Balance at the end of the year (in dollars per share)	3.82	$ 4.50	$ 5.26	$ 6.05
Vested or Expected to vest at the end of the year (in dollars per share)	3.90
Exercisable at the end of the year (in dollars per share)	$ 4.73
Weighted Average Remaining Contractual Life (In Years)
Balance	8 years 14 days	7 years 11 months 19 days	6 years 1 month 28 days	5 years 5 months 1 day
Vested or Expected to vest at the end of the year	7 years 10 months 24 days
Exercisable at the end of the year	6 years 5 months 19 days
Aggregate Intrinsic Value (in thousands)
Balance at the beginning of the year		$ 11	$ 60	$ 191

Stock Incentive Plan and Empl_7

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Information about Outstanding and Exercisable Options (Details) - Stock options shares in Thousands	12 Months Ended
	Jun. 30, 2020$ / sharesshares
Options Outstanding
Number Outstanding | shares	5,956
Weighted-Average Remaining Contractual Life (Years)	8 years 14 days
Weighted-Average Exercise Price (in dollars per share)	$ 3.82
Options Exercisable
Number Outstanding | shares	2,109
Weighted-Average Exercise Price (in dollars per share)	$ 4.73
$2.60 – 2.60
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	2.60
Exercise price, high end of range (in dollars per share)	$ 2.60
Options Outstanding
Number Outstanding | shares	1,815
Weighted-Average Remaining Contractual Life (Years)	9 years 4 months 2 days
Weighted-Average Exercise Price (in dollars per share)	$ 2.60
$2.96 – 4.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	2.96
Exercise price, high end of range (in dollars per share)	$ 4.01
Options Outstanding
Number Outstanding | shares	764
Weighted-Average Remaining Contractual Life (Years)	7 years 9 months 10 days
Weighted-Average Exercise Price (in dollars per share)	$ 3.60
Options Exercisable
Number Outstanding | shares	326
Weighted-Average Exercise Price (in dollars per share)	$ 3.99
$4.10 – 4.10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	4.10
Exercise price, high end of range (in dollars per share)	$ 4.10
Options Outstanding
Number Outstanding | shares	2,543
Weighted-Average Remaining Contractual Life (Years)	8 years 5 months 1 day
Weighted-Average Exercise Price (in dollars per share)	$ 4.10
Options Exercisable
Number Outstanding | shares	1,007
Weighted-Average Exercise Price (in dollars per share)	$ 4.10
$4.23 – 7.70
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	4.23
Exercise price, high end of range (in dollars per share)	$ 7.70
Options Outstanding
Number Outstanding | shares	826
Weighted-Average Remaining Contractual Life (Years)	4 years 3 months 14 days
Weighted-Average Exercise Price (in dollars per share)	$ 5.77
Options Exercisable
Number Outstanding | shares	768
Weighted-Average Exercise Price (in dollars per share)	$ 5.82
$8.01 – 8.01
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	8.01
Exercise price, high end of range (in dollars per share)	$ 8.01
Options Outstanding
Number Outstanding | shares	2
Weighted-Average Remaining Contractual Life (Years)	1 year
Weighted-Average Exercise Price (in dollars per share)	$ 8.01
Options Exercisable
Number Outstanding | shares	2
Weighted-Average Exercise Price (in dollars per share)	$ 8.01
$8.89 – 8.89
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise price, low end of range (in dollars per share)	8.89
Exercise price, high end of range (in dollars per share)	$ 8.89
Options Outstanding
Number Outstanding | shares	6
Weighted-Average Remaining Contractual Life (Years)	9 months 29 days
Weighted-Average Exercise Price (in dollars per share)	$ 8.89
Options Exercisable
Number Outstanding | shares	6
Weighted-Average Exercise Price (in dollars per share)	$ 8.89

Stock Incentive Plan and Empl_8

Stock Incentive Plan and Employee Stock Purchase Plan - Summary of Activity of RSUs, PSUs and MSUs (Details) - $ / shares	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Restricted Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	3,084,000	3,700,000	3,884,000
Granted (in shares)	2,009,000	1,386,000	1,529,000
Vested (in shares)	(1,579,000)	(1,481,000)	(1,167,000)
Cancelled/Forfeited (in shares)	(343,000)	(521,000)	(546,000)
Unvested at the end of the year (in shares)	3,171,000	3,084,000	3,700,000
Weighted Average Grant Date Fair Value Per Share
Granted (in dollars per share)	$ 2.74	$ 3.68	$ 4.57
Performance Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)		63,000	10,000
Granted (in shares)	419,000	0	53,000
Vested (in shares)	0	(10,000)	0
Cancelled/Forfeited (in shares)		(53,000)
Unvested at the end of the year (in shares)	419,000		63,000
Market Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	641,000	1,397,000	1,333,000
Granted (in shares)	0	0	654,000
Vested (in shares)	0	0	0
Cancelled/Forfeited (in shares)	(470,000)	(756,000)	(590,000)
Unvested at the end of the year (in shares)	171,000	641,000	1,397,000
Weighted Average Grant Date Fair Value Per Share
Granted (in dollars per share)			$ 4.11
Restricted Stock Units, Performance Stock Units and Market Stock Units
Total Number of Shares Underlying
Unvested at the beginning of the year (in shares)	3,725,000	5,160,000	5,227,000
Granted (in shares)	2,428,000	1,386,000	2,236,000
Vested (in shares)	(1,579,000)	(1,491,000)	(1,167,000)
Cancelled/Forfeited (in shares)	(813,000)	(1,330,000)	(1,136,000)
Unvested at the end of the year (in shares)	3,761,000	3,725,000	5,160,000
Weighted Average Grant Date Fair Value Per Share
Unvested at the beginning of the year (in dollars per share)	$ 4.34	$ 5.03	$ 5.75
Granted (in dollars per share)	2.74	3.68	4.40
Vested (in dollars per share)	4.62	5.44	6.24
Cancelled/Forfeited (in dollars per share)	3.96	5.10	5.87
Unvested at the end of the year (in dollars per share)	$ 4.34	$ 4.34	$ 5.03

Stock Incentive Plan and Empl_9

Stock Incentive Plan and Employee Stock Purchase Plan - ESPP (Details) - ESPP	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Weighted average assumptions used for determining fair value of options
Risk-free interest rate, Minimum (as a percent)	0.17%	2.11%	1.07%
Risk-free interest rate, Maximum (as a percent)	1.60%	2.72%	2.28%
Expected volatility, Minimum (as a percent)	45.46%	30.90%	31.30%
Expected volatility, Maximum (as a percent)	75.21%	60.00%	51.10%
Minimum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	6 months	6 months	6 months
Maximum
Weighted average assumptions used for determining fair value of options
Expected term (in years)	1 year	1 year	1 year

Joint Venture - Additional Info

Joint Venture - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jan. 31, 2019
Schedule Of Equity Method Investments [Line Items]
Gain on contribution to joint venture		$ 12,964,000
Elimination of equity method investment intra-entity profit on sales		1,847,000
Accumulated deficit		(481,713,000)	$ (485,540,000)
Goodwill		57,717,000	57,770,000	$ 57,855,000
Impairment of goodwill		$ 0	$ 0	$ 0
Accuray Asia
Schedule Of Equity Method Investments [Line Items]
Percentage of ownership interest in joint venture		49.00%			49.00%
Gain on contribution to joint venture	$ 13,000,000
Elimination of equity method investment intra-entity profit on sales		$ 1,800,000
Proportion of recognizing joint venture income or loss		49.00%
Accumulated deficit		$ 100,000
Equity method investment		13,900,000
Proportional share of underlying equity in net assets		10,900,000
Equity method investment, intra-entity profit		1,800,000
Difference in equity method investment		3,000,000
Goodwill		4,800,000
Impairment of goodwill		$ 0

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income (Loss) Before Provision for Income Taxes on the Accompanying Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Components of income (loss) before provision for income taxes
Domestic	$ (1,811)	$ (23,799)	$ (30,747)
Foreign	7,501	9,455	7,726
Income (loss) before provision for income taxes	$ 5,690	$ (14,344)	$ (23,021)

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Current:
State	$ 15	$ 32	$ 63
Foreign	1,495	2,140	785
Total current	1,510	2,172	848
Deferred:
Foreign	353	(86)	30
Total deferred	353	(86)	30
Total provision for income taxes	$ 1,863	$ 2,086	$ 878

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2017
Income Taxes [Line Items]
Income tax payable		$ 800	$ 1,600	$ 1,100
Valuation allowance percentage established for domestic and foreign net deferred tax assets		100.00%
Undistributed earnings of foreign subsidiaries		$ 45,200
Reduction in uncertain tax position due to lapse of various statutes of limitation		$ 10
Subsequent period within which no material changes in unrecognized tax benefits are expected		12 months
Gross unrecognized tax benefits		$ 16,996	16,280	$ 15,299	$ 15,819
Uncertain tax benefits that, if realized, would affect the effective tax rate		16,800
Accrued interest and penalties related to uncertain tax positions		10	$ 60
Minimum
Income Taxes [Line Items]
Average annual prior gross receipts treshhold amount for exemption from base erosion and anti abuse tax		$ 500,000
Statutes of limitations with respect to jurisdictions (in years)		3 years
Maximum
Income Taxes [Line Items]
Statutes of limitations with respect to jurisdictions (in years)		10 years
Marginal Rate
Income Taxes [Line Items]
Effective income tax rate	35.00%
Flat Rate
Income Taxes [Line Items]
Effective income tax rate		21.00%
Federal
Income Taxes [Line Items]
Net operating loss carryforwards		$ 322,100
Federal | Research and development
Income Taxes [Line Items]
Tax credits		22,000
State
Income Taxes [Line Items]
Net operating loss carryforwards		139,100
State | Research and development
Income Taxes [Line Items]
Tax credits		$ 20,400

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Taxes at the Statutory Federal Income Tax Rate to the Provision for Income Taxes Included in the Accompanying Consolidated Statements of Operations and Comprehensive Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
U.S. federal taxes (benefit):
At federal statutory rate	$ 1,195	$ (3,012)	$ (6,446)
State tax, net of federal benefit	15	32	63
Share-based compensation expense	810	1,128	1,712
Debt extinguishment			967
Other non-deductible permanent items	418	486	702
R&D credits	(635)	(877)	(142)
Foreign taxes	273	(38)	(1,295)
Other	(69)	58	(228)
Transition Tax			3,348
Tax Cuts and Jobs Act			54,072
Global Intangible Low-Taxed Income	1,185	1,924
Change in valuation allowance	(1,329)	2,385	(51,875)
Total provision for income taxes	$ 1,863	$ 2,086	$ 878

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Deferred tax assets:
Federal and state net operating losses	$ 75,615	$ 77,228
Accrued expenses and reserves	4,972	7,497
Lease liability	5,366
Deferred revenue	5,038	2,897
R&D Credits	22,843	22,108
Share-based compensation expense	1,337	1,327
Capitalized research and development	2,683	3,343
Unicap	2,105	1,953
Fixed assets/intangibles	1,199	1,323
Section 163(j) interest	1,823	1,857
Other	1,290	1,582
Total deferred tax assets	124,271	121,115
Deferred tax liabilities:
Contract acquisition costs	(977)	(1,146)
Right of use assets	(4,508)
Total deferred tax liabilities	(5,485)	(1,146)
Valuation allowance	(118,300)	(119,125)
Net deferred tax assets	$ 486	$ 844

Income Taxes - Schedule of Aggr

Income Taxes - Schedule of Aggregate Changes in the Balance of Gross Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Aggregate changes in the balance of gross unrecognized tax benefits
Balance at beginning of year	$ 16,280	$ 15,299	$ 15,819
Tax positions related to current year: Additions	954	934	823
Tax positions related to prior years: Additions	286	580
Tax positions related to prior years: Reductions	(524)	(533)	(1,343)
Balance at end of year	$ 16,996	$ 16,280	$ 15,299

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Compensation And Retirement Disclosure [Abstract]
Employer's contribution to the 401(k) Plan	$ 2	$ 2.1	$ 2.2

Defined Benefit Pension Oblig_3

Defined Benefit Pension Obligation - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Defined Benefit Pension Obligation
Actuarial gain	$ 600
Defined benefit pension plan
Defined Benefit Pension Obligation
Actuarial gain	615	$ (742)
Employer contributions	1,327	$ 1,373	$ 1,300
Expected total contributions to defined benefit pension plan for fiscal year 2021	$ 1,100
Defined benefit pension plan | BVG
Plan Assets
Guaranteed interest rate for mandatory retirement savings (as a percent)	1.00%
Long-term other liabilities
Defined Benefit Pension Obligation
Unfunded liability	$ 4,500

Defined Benefit Pension Oblig_4

Defined Benefit Pension Obligation - Obligations and Funded Status (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Change in benefit obligation:
Actuarial (gain)/loss	$ (600)
Amounts recognized within the consolidated balance sheets:
Assets	490,927	$ 438,181
Defined benefit pension plan
Change in benefit obligation:
Benefit obligation—beginning of fiscal year	17,577	14,254
Service cost	2,003	1,865	$ 1,887
Interest cost	62	128	97
Plan participants’ contributions	2,886	1,818
Plan amendment	975
Actuarial (gain)/loss	(615)	742
Foreign currency changes	545	250
Benefit and expense payments	(5,007)	(1,480)
Benefit obligation—end of fiscal year	18,426	17,577	14,254
Change in plan assets:
Plan assets—beginning of fiscal year	14,228	12,192
Employer contributions	1,327	1,373	1,300
Actual return on plan assets	112	122
Plan participants’ contributions	2,885	1,818
Foreign currency changes	413	203
Benefit and expense payments	(5,007)	(1,480)
Plan assets—end of fiscal year	13,958	14,228	$ 12,192
Funded status	(4,468)	(3,349)
Amounts recognized within the consolidated balance sheets:
Long-term other liabilities	4,468	3,349
Net amount recognized	$ 4,468	$ 3,349

Defined Benefit Pension Oblig_5

Defined Benefit Pension Obligation - Amounts Recognized (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Amounts recognized within the consolidated balance sheets:
Assets	$ 490,927	$ 438,181
Defined benefit pension plan
Amounts recognized within the consolidated balance sheets:
Long-term other liabilities	(4,468)	(3,349)
Net amount recognized	(4,468)	(3,349)
Amounts recognized in accumulated other comprehensive loss (before tax)
Net loss	(1,000)	(144)
Total recognized in other comprehensive income (loss)	(236)	(856)	$ 973
Accumulated other comprehensive loss	(1,236)	(1,000)
Accumulated benefit obligations in excess of fair value of plan assets:
Projected benefit obligation	18,426	17,577
Accumulated benefit obligation	16,175	15,506
Fair value of plan assets	$ 13,958	$ 14,228

Defined Benefit Pension Oblig_6

Defined Benefit Pension Obligation - Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Loss (Details) - Defined benefit pension plan - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2021
Net Periodic Benefit Costs:
Service cost	$ 2,003	$ 1,865	$ 1,887
Interest cost	62	128	97
Expected returns on assets	(151)	(170)	(156)
Amortization of prior service cost	(2)	(55)	(44)
Amortization of net loss			11
Settlement charges	178
Net periodic benefit costs	2,090	1,768	1,795
Other Amounts Recognized in Other Comprehensive Loss:
Net (gain) loss arising during the year	(593)	801	(901)
Prior service cost	2		(105)
Amortization of prior service cost	1,005	55	44
Amortization of net gain			(11)
Effect of settlement	(178)
Total recognized in other comprehensive (gain) loss	236	856	(973)
Total recognized in net periodic benefit costs and other comprehensive loss	$ 2,326	$ 2,624	$ 822
Scenario Forecast
Amounts in accumulated other comprehensive loss that are expected to be recognized as components of net periodic benefit cost during fiscal year 2020
Net loss				$ 852
Prior service credit				506
Accumulated other comprehensive loss				$ 1,358

Defined Benefit Pension Oblig_7

Defined Benefit Pension Obligation - Assumptions (Details) - Defined benefit pension plan	12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Net Periodic Benefit Costs:
Discount rate (as a percent)	0.25%	0.45%	0.90%
Rate of compensation increase (as a percent)	1.50%	1.50%	1.50%
Expected long-term return on assets (as a percent)	1.00%	1.20%	1.40%
Benefit Obligation:
Discount rate (as a percent)	0.25%	0.45%
Rate of compensation increase (as a percent)	1.50%	1.50%

Defined Benefit Pension Oblig_8

Defined Benefit Pension Obligation - Estimated Contributions and Future Benefit Payments (Details) - Defined benefit pension plan $ in Thousands	Jun. 30, 2020USD ($)
Future Benefit Payments
2021	$ 2,344
2022	816
2023	746
2024	688
2025	763
Thereafter	3,189
Total	$ 8,546

Segment Disclosure - Additional

Segment Disclosure - Additional Information (Details)	12 Months Ended
	Jun. 30, 2020segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Segment Disclosure - Summary of

Segment Disclosure - Summary of Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020		Jun. 30, 2019		Jun. 30, 2018
Segment Information
Total net revenue	$ 94,977	$ 99,548	$ 98,826	$ 89,577	$ 117,417	$ 103,221	$ 102,318	$ 95,829	$ 382,928	[1]	$ 418,785	[1]	$ 404,897	[1]
Americas
Segment Information
Total net revenue									128,562		135,683		145,689
Europe, Middle East, India and Africa
Segment Information
Total net revenue									119,989		149,095		120,032
Asia (excluding Japan and India)
Segment Information
Total net revenue									61,689		63,793		72,925
Japan
Segment Information
Total net revenue									$ 72,688		$ 70,214		$ 66,251
[1]	Includes sales to the China joint venture, an equity method investment of $19,054 for the year ended June 30, 2020 and $0 for both years ended June 30, 2019 and June 30, 2018, respectively. See Note 13.

Segment Disclosure - Schedule o

Segment Disclosure - Schedule of Geographic Areas in Which the Company has Long-Lived Tangible Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2019
Segment Information
Long lived tangible assets	$ 15,349	$ 17,122
Americas
Segment Information
Long lived tangible assets	12,807	13,853
Europe, Middle East, India and Africa
Segment Information
Long lived tangible assets	373	575
Asia (excluding Japan and India)
Segment Information
Long lived tangible assets	986	1,419
Japan
Segment Information
Long lived tangible assets	$ 1,183	$ 1,275

Restructuring Charges (Details)

Restructuring Charges (Details) - USD ($)	May 27, 2020	Oct. 31, 2018	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Restructuring and Severance Charges
Accrued restructuring charges			$ 600,000	$ 500,000
Employee severance
Restructuring and Severance Charges
Workforce affected by cost saving initiative (as a percent)	3.00%	5.00%
Restructuring charges			500,000	1,000,000	$ 0
Employee severance | Cost of Goods Sold and Operating Expense
Restructuring and Severance Charges
Restructuring charges			$ 1,100,000	$ 1,500,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Events - Term Loan Agreement $ in Millions	Jul. 03, 2020USD ($)
Subsequent Event [Line Items]
Principal prepayment of term loan	$ 10
Amendment fee	$ 0.5

Quarterly Financial Data (una_3

Quarterly Financial Data (unaudited) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2020		Jun. 30, 2019		Jun. 30, 2018
Quarterly Financial Data [Abstract]
Net revenue	$ 94,977	$ 99,548	$ 98,826	$ 89,577	$ 117,417	$ 103,221	$ 102,318	$ 95,829	$ 382,928	[1]	$ 418,785	[1]	$ 404,897	[1]
Gross profit	39,745	39,133	37,900	32,943	45,926	40,466	38,380	37,879	149,721		162,651		161,695
Net income (loss)	$ (152)	$ 2,625	$ 10,710	$ (9,356)	$ (1,400)	$ (1,184)	$ (4,640)	$ (9,206)	$ 3,827		$ (16,430)		$ (23,899)
Net income (loss) per share - basic	$ 0	$ 0.03	$ 0.12	$ (0.11)					$ 0.04		$ (0.19)		$ (0.28)
Net income (loss) per share - diluted	$ 0	$ 0.03	$ 0.12	$ (0.11)					$ 0.04		$ (0.19)		$ (0.28)
Weighted average common shares used in computing net income (loss) per share:
Basic	90,748	90,476	89,517	88,772					89,874		87,465		84,893
Diluted	90,748	90,855	90,279	88,772					90,623		87,465		84,893
Net loss per share—basic and diluted					$ (0.02)	$ (0.01)	$ (0.05)	$ (0.11)
Shares used in basic and diluted per share calculation					88,202	87,962	87,237	86,479
[1]	Includes sales to the China joint venture, an equity method investment of $19,054 for the year ended June 30, 2020 and $0 for both years ended June 30, 2019 and June 30, 2018, respectively. See Note 13.